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ABSTRACT 
The American University in Cairo 
Investigating circulatory microRNA expression profiles for 
Egyptian patients affected with HCV mediated 
hepatocellular carcinoma. 
By: Amany Mohamed Mohamed Mahmoud Al-Anany 
Under the supervision of: Prof. Dr. Hassan M.E. Azzazy 
 
Hepatitis C virus (HCV) infection is a serious health challenge affecting over 
185 million individuals globally. Egypt has the highest rate for chronic HCV infection 
worldwide. Recent studies have shown that from 10%-30% of HCV infected 
individuals would progress to more deteriorating conditions such as cirrhosis and/or 
hepatocellular carcinoma (HCC). Current biomarkers for HCC diagnosis are lacking 
both sensitivity and specificity. As a result there is demand to develop reliable 
biomarkers that are sensitive, specific and non-invasive for early diagnosis and rapid 
intervention of HCC to increase the survival rate of patients. Recently, circulatory mi-
RNAs have drawn great attention as promising non-invasive biomarkers for various 
diseases. They are highly stable in blood and their expression profiles reflect disease 
progression and/or drug response status. Besides, a number of miRNAs were found to 
be commonly dysregulated in HCC. 
In this study, we investigated mi-RNA expression profile from the plasma of 
Egyptian patients with chronic hepatitis C, cirrhosis and HCV associated HCC 
compared with healthy control. We aimed to assess the diagnostic potential of the 
selected miRNAs to differentiate between healthy, HCV and HCV associated 
disorders (cirrhosis and HCC). In addition to studying the expression pattern in the 
different studied stages.  
Using real time PCR, we compared the levels of circulating mir-122, miR-21 
and miR-155 in plasma from healthy control (n=40), cirrhosis (n=39) and HCC 
(n=40) to CHC (n=37). Synthetic miR-39 was spiked in the samples to be used as a 
normalizing control for the samples.  Plasma miR-122 was significantly up-regulated 
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in HCC than in the three other categories (P<0.001). The plasma level of miR-122 in 
HCC patients was significantly higher than healthy control and cirrhotic patients (P = 
0.002 and P<0.001, respectively). The plasma level of miR-21 was significantly up-
regulated in HCC compared to cirrhotic patients (P=0.03). Although Control and 
HCC in mir-21 increased by 3.52 and 6 log2 scale respectively, they were in marginal 
insignificance (p=0.093) that might be due to limited number of samples used in this 
study. There had been no significant dys-regulation in the expression levels of miR-
155 between the 4 categories. 
 Receiver operating characteristic curves’ analysis revealed that miR-122 
differentiated HCC patients from healthy control with a specificity and sensitivity 
57.50% and 65.52% respectively (at a cutoff >1.86). To discriminate cirrhotic patients 
from HCC subjects, a specificity and sensitivity of 61.54% and 1.43% (at a cutoff> 
0.43) were determined. Additionally, analyzing ROC curve indicated that miR-21 
differentiated HCC patients from cirrhotic patients with best sensitivity and specificity 
72.97% and 50% (at a cutoff >-0.43). 
In conclusion, plasma miR-122 and miR-21 may be further investigated as 
potential markers for HCV associated HCC. 
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Chapter 1 INTRODUCTION 
1.1 Overview 
Hepatitis C virus (HCV) infection is a serious health challenge affecting over 
185 million individuals globally. Egypt has the highest rate for chronic HCV infection 
globally. Unresolved chronic HCV infection could progress to more deteriorating 
conditions such as cirrhosis and/or hepatocellular carcinoma (HCC). The latter is 
estimated to be the second leading cause for cancer related mortalities and the seventh 
most common cancer globally. Current conventional HCC biomarkers lack both 
sensitivity and specificity. Discovering novel and reliable biomarkers that are 
sensitive, specific and non-invasive is very crucial for early diagnosis and rapid 
intervention for HCV related liver diseases. Recently, circulatory mi-RNAs have 
drawn great attention as promising non-invasive biomarkers for various diseases. 
They are highly stable in blood and their expression profiles reflect disease 
progression and/or drug response status. The aim of this study is to explore expression 
profiles for some circulatory mi-RNAs such as miR-122, miR-155 and miR-21 in 
healthy controls, cirrhotic and HCC Egyptian patients against chronic HCV samples. 
Comparative mi-RNAs profiling results could be utilized as novel biomarkers for 
early diagnosis and prognosis of HCV related liver diseases. 
1.2 Research Problem and objectives 
One of the major global health issues is hepatitis C virus infection (HCV). 
Two types of assays are available for determining the occurrence of HCV infection. 
The first test is a serological immunoassay that detects antibody raised against HCV 
infection following week 10.  The second one is a polymerase chain reaction (PCR) 
based molecular assay that detects presence of HCV RNA within few days following 
infection. Although serological immunoassay is efficient, it can't discriminate 
between active and resolved HCV infection. The only disadvantage concerning PCR 
assay is its extreme expensive costs compared to immune-assay [1].  
The progression of HCC is mainly due to the delay in diagnosis and treatment 
[2]. Traditional biomarkers show poor performance in the surveillance, diagnosis and 
prognosis of HCC [3]. Recent studies have indicated that AFP and des γ-carboxy 
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prothrombin (DCP) tests lack adequate specificity and sensitivity for effective 
surveillance and diagnosis [2]. AFP in particular is currently not considered as an 
ideal test for HCC diagnosis by the American association for the study of liver 
diseases. This necessitates the search for novel and potential biomarkers that could 
scan the progression of liver deterioration across various stages to enable early 
diagnosis and intervention [3].  
The overall goal of this thesis is to investigate if the selected mi-RNAs could 
be used as novel biomarkers for early diagnosis and prognosis of several stages of 
HCV-associated liver diseases as an alternative to existing biomarkers. The specific 
objectives are: (1) collect clinical specimens from healthy control, patients infected 
with HCV at different stages and subjects diagnosed with HCC. (2) Develop real-time 
PCR for detection of mi-RNAs in spiked plasma. (3) Explore the expression profiles 
for circulatory mi-RNAs (miR-122, miR-155 and miR-21), as non-invasive method, 
in Egyptian patients affected with various degrees of HCV infection stages. (4) 
Elucidate the correlation between one or panel of mi-RNAs and HCC. (5) Study the 
correlation between some clinical data and mi-RNAs expression. 
1.3 Methodology 
To achieve the study objectives listed above, 156 Egyptian individuals were enrolled 
in the study and divided into groups as follows; (37) chronic HCV infected patients, 
(39) HCV mediated cirrhotic patients, (40) HCV mediated HCC infected patients and 
(40) healthy controls group. All samples were collected from the National Hepatology 
and Tropical Medicine Research Institute (NHTMRI) in Cairo under thorough 
supervision of Prof. Dr. Mohamed Ezz El Arrab the head of the HCC and intervention 
unit at the NHTMRI in Cairo. 
Total RNA and mi-RNA were extracted from patients’ and healthy controls’ 
plasma. RNA purity and concentration were evaluated by Nano-Drop. Extracted RNA 
was poly adenylated, reverse transcribed. This step was followed by quantitative RT-
PCR for the synthesized cDNA. Finally statistical analysis of the data was achieved 
using SPSS software.  
1.4 Organization of the thesis 
This thesis is divided into five chapters. The first chapter is an introduction 
that involves an overview, the research problem, the study objectives and finally the 
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methodology. Chapter 2 displays a literature review of hepatitis C virus and mi-RNA. 
Chapter 3 presents a discussion of the criteria of subjects enrolled in the study and the 
methods utilized. The results and statistical analysis are discussed in Chapter 4. A 
discussion of the results was presented in Chapter5. Finally, a summary of the 
conclusions drawn from this study and future perspectives are presented in chapter 6.
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Chapter 2 LITERATURE REVIEW 
2.1 History of hepatitis C virus 
In 1989 Michael Houghton and his colleagues at the Chiron Corporation in 
Emeryville, CA, together with another team in the Centers for Disease Control in 
Atlanta, GA were able to discover Hepatitis C virus (HCV).  HCV infection was 
known before that time as post-transfusion non-A, non-B hepatitis NANBH [4].   The 
NANBH was postulated to be caused by a small enveloped RNA virus which is 
readily communicable to Chimpanzees [5]. At that time, HCV infection was first 
thought to be of minimal importance, affecting a number of drug users and 
populations experiencing blood transfusion in developed countries [6]. 
  Hepatitis C virus discovery launched a new research era, given that it was the 
primary virus which was detected only by a molecular approach that was based on 
cloning of complementary DNA (cDNA) isolated from infected plasma. The detection 
process was achieved with no tissue culture, electron microscopy or serology 
approaches but with a direct molecular approach based on viral genome cloning. 
Since HCV discovery, it has been considered as one of the major causes for chronic 
liver diseases, cirrhosis, hepatocellular carcinoma HCC and different types of 
hepatitis including post-transfusion and intravenous drug injection mediated hepatitis 
[7].  
2.2 Epidemiology of hepatitis C virus infection 
More than quarter a century after HCV discovery, HCV is currently 
recognized as a global health issue [6]. In 2015, the estimated mortality caused by 
viral hepatitis was 1.34 million deaths which was higher than that caused by HIV and 
comparable to that caused by tuberculosis. While the incidence rate of tuberculosis 
and HIV deaths is apparently declining over time, deaths from viral hepatitis is rising 
(Figure 1) [8]. 
Hepatitis C universal prevalence estimates, built upon the presence of anti-
HCV antibodies has been approximated at 1.6% (range: 1.3–2.1%), which is 
equivalent to 115 million (range: 92–149 million) patients. Yet, these individuals are 
not all currently HCV-infected; certain population have cleared the viral infection 
5 
either spontaneously or as a result of therapy. Accordingly, the viraemic prevalence 
which is based on being positive for HCV RNA is dropped to 1% (range: 0.8–1.14%) 
or 71 million (range: 62–79 million) individuals with HCV infection (Figure 2) [9]. 
 Over the last 15 years, estimates have shown that HCV infection has 
increased to 2.8% of the whole population and this means that more than 185 million 
individuals are affected with HCV. This increase in the disease prevalence is mainly 
due to multiple drug injections and hemodialysis [10]. According to the 2017 World 
Health Organization (WHO) global hepatitis report, 399 thousand lose their lives each 
year to HCV. The majority of these losses are due to cirrhosis and hepatocellular 
carcinoma.       Worldwide, in 2015 the estimated figure for chronically affected HCV 
patients was 71 million.  The Eastern Mediterranean Region has the highest 
prevalence (2.3%) of the world population followed by the Western pacific and the 
European Region (1.5%) (Figure 3) [8]. Cameroon, Egypt, Gabon, Georgia, 
Mongolia, Nigeria and Uzbekistan all have more than 5% prevalence of anti-HCV 
antibody between adult population [9, 11]. Of the total global HCV infections, 
Genotype 4 (GT 4) comprises 12%-15% of the cases, and is the predominant HCV 
epidemic in Egypt, particularly subtype 4a. Approximately, 2-4% of HCV-infected 
individuals can eventually progress to irreversible cirrhosis and/or hepatocellular 
carcinoma (HCC) on a yearly basis [1].  In Egypt the starting cause for HCV infection 
spread was the intravenous treatment for schistosomiasis (bilharzia) in the 1960–
1970s [9, 11]. 
A primary cause for hepatic related mortality, cirrhosis and HCC in the USA 
is HCV infection, which makes it a serious public health problem [12].  Hepatitis C is 
the main signal for liver transplantation in many segments of the world [13]. There is 
still new incidences of HCV infection each year which are estimated to be up to 4 
million new infections. This is due to the sustained use of improperly screened blood 
transfusions and blood products, the use of inadequately sterilized medical tools, and 
the growth in injectable drug handling in formerly unaffected regions. The majority of 
HCV infected patients’ progress from acute to chronic infection without being aware 
of the disease or its progression [14]. 
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2.3 HCV virology 
A massive analysis of the virus’ genome after its discovery in 1989 has 
elucidated its structure. It is well known as an enveloped virus, of diameter ranging 
from 50-80nm and a member of the family Flaviviridae that comprises foremost 
human and animal pathogens. The viral particle is made up of a viral envelop which is 
made up of a lipid bi-layer and on the envelope there are surface proteins. A protein 
capsule known as nucleocapsid is then found inside the envelop that protects the viral 
genetic material (Figure 4) [15, 16].  
HCV genome consists of a positive-sensed or a plus stranded RNA molecule 
of about 9.6 kilo-bases. Plus stranded RNA is running from the 5’-prime end to the 
3’-prime end and could be easily translated to a large poly-protein (around 3000 
amino acids). This large poly-protein is a precursor to at least 10 proteins: the core, 
envelope 1 (El), E2, p7, nonstructural (NS) 2, NS3, NS4A, NS4B, NS5A, and NS5B 
(Figure 5).  The viral structural proteins are the core protein (C) and the envelope 
glycoproteins E1 and E2. Then comes a small membrane bound protein p7 which acts 
as an ion channel. The remaining proteins play a key role in the intracellular life cycle 
of the virus. The ten former proteins are readily released from the cleavage of the 
precursor by proteinase enzymes of the host and the virus itself. These HCV proteins 
play a very important role not only in viral replication but also in multiple cellular 
functions [15, 17].  
An important feature of HCV infection is the heterogeneity of the virus 
density circulating in blood. It varies from very low to low, intermediate and high 
density fractions. Very low to low density HCV fractions are called Lipo-Viro-
Particle (LVP) in which the virus is linked to triglyceride-rich lipoproteins (TRL) 
these include apo-lipoproteins B, C1, C2, C3 and E. High density virions are mainly 
composed of naked nucleocapsids; which is the viral genome interacting with the core 
protein, while those of intermediate density appear in an enveloped viral form which 
is known as “canonical” form [18]. 
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2.4 HCV Life cycle  
2.4.1 HCV entry and un-coating 
Hepatitis C viral infection is well known only in humans and chimpanzees. It 
is mainly transmitted through blood including wrong blood transfusion from HCV 
infected subjects or contaminated blood products, insecure medical treatment, dialysis 
and medical operation  In Egypt, the main reason for HCV epidemic is the 
intravenous injection therapy for anti-schistosomiasis. Besides the lack of disposable 
syringes and the improper use of health care facilities made the prevalence of the 
infection became faster [19]. 
Hepatitis C virus reaches the liver through the bloodstream. Even though HCV 
infection was reported in other cells than hepatocytes such as B cells, dendritic cells 
and others, productive infection of HCV occurs only within hepatocytes (Figure 6). 
In other words, hepatocytes are the only human cells that support HCV replication 
which makes this viral infection unique [18, 20]. The virus comes in contact with 
hepatocytes through the passage across liver sinusoids which are types of blood 
vessels with fenestrated, discontinuous endothelium [21]. 
Upon reaching the hepatocyte surface, the viral particle interacts first with the 
surface receptors and attachment factors. This step is mediated by Low density 
lipoprotein receptor (LDLR), glycosaminoglycans (GAGs) and heparan sulfate 
proteoglycan syndecan-1 or syndecan-4 or by the scavenger receptor class B type1 
(SRB1). The viral interaction with these receptors, based on the viral particles’ 
density, is initiated by binding to Apo-lipoprotein E (APoE) which resides on LDLR 
[20]. This is then followed by binding to more specific receptors, including the 
scavenger receptor B1 and the tetraspanin protein (CD81). The new complex of the 
viral particle with these entry factors reaches tight junction and participates in future 
interactions with claudin-1 (CLDN1) and occlud (OCLN) [21, 22, 23]. The lateral 
membrane transfusion is actin-mediated and depends on the activation of many 
transduction pathways [22]. 
The viral particle consecutively goes into the cell via receptor-and clathrin 
mediated endocytosis. After reaching the cytosol, the clathrin-coated vesicle is 
transported along microtubules to reach Ras-related protein Rab-5A (RAB5A) 
containing the endoplasmic reticulum area where HCV fusion occurs. At low PHs, the 
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endosome lumen provokes conformational modifications of the viral envelop 
glycoproteins, that successively triggers a fusion process of viral and endosomal 
membranes. Following membrane fusion a process of nucleocapsid un-coating is 
achieved leading to the release of the Viral RNA genome into the cytosol [22, 23]. 
2.4.2 HCV RNA translation 
Binding and gathering of ribosome subunit on the viral RNA is the initial unit 
of hepatitis C virus polyprotein translation which would subsequently initiate viral 
replication. A signal sequence sited at the viral 5ʹ non coding region (NCR) allows 
the ribosome to be targeted to the translocation channel on the endoplasmic reticulum 
(ER) membrane. The 5′-NCR comprises four highly well-organized domains running 
from I to IV. Domain I and II play a crucial role in HCV RNA replication and domain 
I is not involved in internal ribosomal entry site (IRES) activity. The IRES is made up 
of 5’-NCR domains II, III and IV in addition to the 20-40 nucleotides at the beginning 
of the core coding sequence of the virus genome [9, 20]. 
The initial step in HCV translation is the development of a complex between 
the IRES and the 40S ribosomal subunit. Subsequently an assembly of eukaryotic 
translation initiation factor 3 (eIF3) and ternary complex (eIF2•Met-tRNAi •GTP) 
occurs. This in turn leads to the association of a 48S-like complex at the AUG 
initiation codon to start translation. The rate limiting step for the translation process is 
the GTP-dependent assembly of the 60S subunit to form an 80S complex [20]. 
Translation can thus be carried on further producing a poly-protein that is processed 
by cellular-endoplasmic reticulum- signal peptidases and by viral proteases into 10 
mature structural and non-structural proteins [9, 20]. Endoplasmic reticulum peptidase 
processes the structural proteins and P7 polypeptide while the two viral proteases, the 
NS2-3 protease and the NS3-4A serine protease process the non-structural proteins. 
The released proteins are either used for translation and replication which is the case 
for non-structural proteins, or packaged into new viral particles.The non-structural 
protein NS2–3 and NS3/4A are having a catalytic protease activity. P7 is an amino 
acid protein that has an ion channel activity. NS4B induces the development of the 
membranous web which is essential for HCV viral replication. NS5B catalyze the 
formation of a complementary negative-strand RNA and the consequent synthesis of 
genomic positive-strand RNA from this negative-strand RNA template [20].  
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2.4.3 HCV RNA replication 
HCV non-structural proteins such as NS3/4A, NS4B, NS5A, and NS5B in 
concert with host factors constitute the replication complex. NS4B integral membrane 
protein would first induce changes in the ER membrane, leading to the development 
of double-membrane vesicles. These vesicles cluster to develop the membranous web, 
which represents the site for HCV viral replication [9]. RNA dependent RNA 
polymerase activity of NS5B, which acts together with other viral non-structural 
proteins, along with several host factors would catalyze the synthesis of a viral RNA 
positive strand. The synthesis of a negative RNA strand intermediate is then 
completed using the positive-strand genome RNA as a template. Multiple positive-
strand RNAs are generated from the negative RNA strand intermediate. These 
multiple positive-strand RNAs are consequently utilized either for translation, the 
preparation of new intermediates for viral replication or packaging into nucleocapsid 
[23]. 
2.4.4 Packaging, assembly and particle release 
Viral particle assembly relies mainly on the presence of lipid droplets (LDs) 
which keep triacylglycerides and cholesteryl esters surrounded by a phospholipid 
monolayer incorporating numerous proteins. It is assumed that core proteins interact 
with LDs to trigger the assembly of other viral components involved in viral particle 
synthesis [21]. LDs act as transporters conveying core protein from  RNA translation 
and replication sites to assembly sites.  NS5A then carries the viral RNA to core 
proteins for assembly into nucleocapsids. Nucleocapsids are formed at the ER and ER 
derived membranes, where E1 and E2 are delivered associated with p7, NS2 and host 
factors including apolipoprotein E. The viral envelop glycoproteins are developed by 
budding, a process which is common in members of the Flaviviridae [24]. Newly 
synthesized virus particles are thought to be transported to Golgi apparatus where they 
would be packed up and placed in endosomes that acts as export vesicles which via 
the cellular secretory pathway would release the new virus particles to the cell 
surface. Finally, by exocytosis they are discharged from the cell to reach the blood 
circulation. It has been reported that HCV can directly infect neighboring cells with 
no need for HCV entry factors [25].    
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2.5 HCV genotypes, subtypes and quasi-species 
Remarkable genetic heterogeneity is a distinguishing feature of HCV genome. 
Genetic diversity exist at several levels including six major genotypes, with various 
subtypes (over 80) and minimal variants formed during evolution called 
“quasispecies”. HCV genotypes are created as a result of accidental nucleotide errors 
that are often introduced by RNA-dependent RNA polymerase during replication of 
HCV genome and due to the lack of associated repair mechanism [26, 27].   Studies 
have revealed that there only six major genotypes each with multiple subtypes and 
that newly proposed genotypes such as 7,8 and 9 are only subtypes of genotype 6 and  
genotype 10 is a subtype of genotype 3B [27, 28].  
Worldwide distribution of HCV genotypes is extensive, which reflects 
dissimilarities in epidemiology, including pathogenesis, diagnostic implications, 
response to therapy and racial variability. The sequence differences among these 
genotypes are momentous which make it rational to believe that viruses 
compromising these genotypes have different traits. For instance, certain HCV 
genotypes seem to have higher response to interferon therapy than others [29].  HCV 
genotypes 1, 2 and 3 have broad geographical distribution, whereas HCV genotypes 
4, 5 and 6 are restricted to definite areas (Figure 7).  The most predominant genotype 
in Africa and the Middle East is genotype 4 with highest prevalence in Egypt. A 
proposed study in 2012 reported the prevalence of HCV in Egypt  about 7 per 1,000 
person-years, which is equivalent to 500,000 HCV infections annually [26], with 85% 
of genotype 4 [30]. HCV genotype1 is mostly prevalent in Argentina while genotype 
2 is mostly prevalent in Taiwan and Republic of Korea. Pakistan, India and Thailand 
are having the highest prevalence of genotype3. Genotype5 main prevalence is in 
South Africa, yet genotype6 is mainly prevalent in Vietnam [26]. 
The main difference between genotypes and quasispecies that the later genetic 
heterogeneity is observed within a single infected individual while genotypes 
heterogeneity is detected among diverse HCV isolates [29]. Quasispecies are 
genetically related variants with only minimal sequence differentiations (i.e., less than 
5% of the viral genome), these variants’ genomes are concentrated around one master 
sequence [27, 29]. The Quasispecies nature of HCV infection can be a reason for 
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persistent infection, altered response to interferon therapy and finally resistance to 
host immune response [29]. 
2.6 HCV and immune response 
In the first weeks of infection, the host evokes innate immune responses, then 
on later weeks, an adaptive immune responses are elicited to clear invading virus C 
[31]. The minority of HCV infected patients that have the ability to clear the viral 
infection is mainly due to a rapid induction of innate immune response. On the other 
hand, most patients are unable to clear the virus and develops viral persistence 
challenging continuing immune responses. This due to the virus multiple strategies 
that are elaborated to avoid these immune responses [32]. 
2.6.1 Innate immune response 
Innate immune response is considered to be a rapid and specific immune 
response, besides being the first line of defense against virus C infection. This kind of 
immune response involves the participation of both natural killer cells (NK) and 
dendritic cells. Natural killer cells would attack the infected hepatocytes causing their 
lyses in addition to its role in shaping the downstream adaptive immune response. 
Dendritic cells (DCs) are professional antigen presenting cells (APC) that has an 
important function in immune surveillance, antigen (Ag) capture, and Ag 
presentation, which in turn provides a bridge between innate and adaptive immune 
responses [31]. 
Upon infection, the virus is recognized by several pathways these include; the toll-like 
receptor (TLR) dependent pathway and the cytosolic pathway. These pathways are 
elicited by interaction between the viral RNA, the RNA helicases retinoic acid 
inducible gene-1 (RIG-1) and melanoma differentiation antigen 5 (Mda5). Both (RIG-
1) and (Mda5) act as pattern recognition receptors that sense virus C infection. The 
key transcription factors NF-jB as well as the interferon regulatory factors (IRF) 3 and 
7 are activated as the toll-like receptor (TLR) and the cytosolic pathway join. 
Activated IRF3 and NF-jB would finally lead to NK cells activation which in turn 
stimulates the release of cytokines (gamma interferon (IFN-γ), tumor necrosis factor-α 
[TNF-α]) and chemokines (macrophage inflammatory factor [MIP-1] α/β and 
interferon γ inducible protein 10 [IP-10]), providing an important front line of defense 
against hepatitis C viral infection [31].  
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All interferons are capable of eliciting an antiviral response upon 
transcriptional activation of hundreds of genes [33].  Type I IFNs (including several 
IFN-α and one IFN-β) and type III IFNs (IFNk1,-k2, and -k3; also termed IL29, 
IL28A, and IL28B) are produced by the infected cells and by key cells of the innate 
immune system: macrophages and dendritic cells [32]. 
2.6.2 Adaptive immune response 
Humoral antibody and T cells are two arms of the adaptive immune system 
that play an important role in hepatitis C viral clearance. After 6-8 weeks of acute 
infection, the former system activity could be detected via producing antibodies 
against epitopes associated with both viral structural and non-structural proteins. 
Studies have shown that only small portion of the released anti bodies, known as 
neutralizing antibodies, is having anti-viral activity by inhibiting virus binding, entry 
or un-coating. CD4+ helper T-cells and CD8+ cytotoxic T-cells are very important 
cells that are directed against multiple epitopes within the different HCV proteins 
[32]. Interestingly, another study have suggested a delayed development of 
neutralizing antibodies and T-cells in patients with chronic infection, but an early time 
development in people with resolving infection. CD4+ cells are in charge of 
stimulation and conservation of successful CD8+ T-cell responses. CD4+ cells migrate 
to the hepatocytes where APCs stimulate CD4+ activity and release of cytokines. This 
in turn causes the maturation of CD8+ which are key modulators in regulating viral 
infection through cytolysis (by perforin cytolytic protein release) and secretion of 
anti-viral cytokines such as IFN-γ (Figure 8) [34,35]. 
2.6.3 Viral escape from immune response 
Studies have proven that HCV has established multiple strategies to not only 
escape but also work against host immune defenses (Figure 9). These are probably 
the main causes that contribute to the persistence of HCV infection. First, the 
association of virus C particles with host lipid proteins such as lipoproteins that 
resembles VLDL particles enables the virus to be masked from recognition by the 
host immune system. Second, the fact that the virus replicates its RNAs within re-
arranged cytoplasmic membrane vesicles which are highly compartmentalized 
microenvironment may protect HCV replication complexes from attacks by cellular 
nucleases and proteinases [33]. Third, Studies have reported that HCV evokes 
autophagy, stimulating the cells to recycle cytoplasmic constituents via lysosomal 
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pathways which eventually enable the virus to escape innate immunity antiviral 
activity [33, 36]. Fourth, miR-122, a liver specific mi-RNA, is known to be hijacked 
by hepatitis C virus to promote and facilitate the replication of its genome [33]. miR-
122 3’end would bind the viral RNA 5’end, leading to viral RNA protection from the 
5' to 3' exonuclease activity and host innate immunity [37]. Fifth, the presence of 
hepatitis C in the form of viral variants named quasispecies allow the virus to escape 
cytotoxic T cells and neutralizing antibodies [33]. Besides, in case of the absence of 
CD4+ T cell help or the effect of regulatory T cells or cytokines may lead to virus-
specific CD8+ T cell exhaustion, enabling HCV escape from the adaptive immune 
response [34]. 
2.7 HCV and liver diseases 
2.7.1 Chronic HCV infection 
Hepatitis C viral infection remains asymptomatic for decades in its acute 
infection stage in the majority of cases before its detection in late chronic stages, 
when noticeable symptoms will be recognized. Acute infection may develop with 
symptoms such as jaundice, fatigue, right upper abdominal pain, discomfort or joint 
pain in minor cases [9]. Up to 85% of HCV Egyptian patients develop chronic 
hepatitis while others experience spontaneous clearance of the virus. On long term 
chronic infection, in which the patient harbor the disease for an average between 20–
40 years, HCV may complicate to liver fibrosis, cirrhosis, and eventually, HCC [30, 
38]. Liver fibrosis is distinguished by excessive deposition of extracellular matrix 
proteins (ECM- proteins) such as collagen which would subsequently alter the liver 
structure by developing a fibrous scar, and then forming nodules of regenerating 
hepatocytes named cirrhosis. Fibrosis is thought to be a model of wound-healing 
response to chronic hepatic damage which is reversible in early stages however if it 
reached a cirrhosis stage it would be irreversible [39].   Cofactors, for instance; patient 
age, male sex, alcohol, HIV infection and schistosomiasis can make the progression 
towards end-stage liver disease goes faster in other words to be having synergistic 
effect [8, 9, 30].  
Cirrhosis may progress to some complications including hepatic 
decompensation which is distinguished by hepatic failure, ascites, upper 
gastrointestinal bleeding, and liver encephalopathy. The later complications, cirrhosis 
and HCC are mostly the causes for mortalities between HCV patients [30]. Patients 
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may suffer from symptoms such as fatigue, weight loss, muscle and joint pain, or 
right upper abdominal discomfort, pain or itching prior to developing decompensation 
symptoms [8, 9, 30]. 
2.7.2 HCV induced HCC 
Nowadays HCC is estimated to be the second leading cause for cancer related 
mortalities and the seventh most common cancer globally [40]. HCC is a highly lethal 
cancer as the majority of the cases are detected at a late stage in patients with 
underlying hepatic dysfunction. There are different etiologies for HCC among these is 
hepatitis B, hepatitis C, alcoholic liver diseases and non-alcoholic fatty liver diseases.  
HCV has been a primary cause of HCC in developed nations and is the first warning 
for hepatic transplantation for patients with HCC in the United States [40, 41]. 
Pathogenesis of HCV-induced HCC involves multiple steps: establishment of acute 
HCV infection, prognosis to chronic infection, chronic hepatitis, gradual liver fibrosis, 
appearance of neoplastic clones associated with permanent somatic genetic/epigenetic 
changes, and finally progression of the malignant clones in an oncogenic tissue 
microenvironment which is usually referred to as “field cancerization” (Figure 10 ). 
This cirrhotic oncogenic microenvironment accelerates genetic abnormalities and 
cellular transformation which in turn allows development and promotion of 
carcinogenic clones. HCV chronic infection, leads to hepatic damage which is 
manifested in the release of inflammatory mediators for instance: reactive oxygen 
species (ROS), cell death signals, nucleotides and hedgehog ligands; proteins that 
regulate cell growth and its fate. A complex series of events then occurs that leads to 
hepatic stellate cell activation. These events include the activation of intracellular 
inflammation factors, a family of transcription factors and other transcriptional events. 
Hepatic stellate cell activation stimulates liver scarring as a result of proliferation, 
fibro-genesis, matrix degradation and inflammatory signaling [40]. 
2.8 Diagnosis of HCV and consequent liver diseases 
2.8.1 Serological assay (Immunoassay)  
A number of virological tools can be utilized for diagnosis and monitoring of 
hepatitis C infection. The frequently used screening tool is immunoassay which 
includes enzyme immunoassay (EIA), micro-particle EIA, chemi-luminescence 
immunoassay (CIA). These assays are based on the ability to detect total anti-HCV 
15 
antibodies (IgG and IgM) in serum, plasma , whole blood or cervicular oral fluid [9].  
They are specific, inexpensive and have easy automation. A limitation of these assays 
that detection cannot distinguish between acute and chronic HCV infection [42]. 
Additionally, testing only for anti-HCV antibodies might miss early infection when 
the amount of antibodies released are non-detectable [9]. The fact that anti-HCV 
antibodies persist for years or even decades in the body ever after the clearance of the 
viral infection make it impossible to discriminate between recovered patients and 
concurrently diagnosed leading to false positive results. To aid in solving false-
positive EIA test problem new supplemental tests (recombinant immune-blot assay 
(RIBA)) were developed. These include second-generation RIBA (RIBA-2) and third-
generation RIBA (RIBA-3) EIAs [43]. Currently, the third-generation EIAs are used 
to detect antibodies directed against several HCV epitopes in plasma or serum. These 
epitopes include recombinant antigens from core and non-structural proteins 3, 4 and 
5 [42].   
2.8.2 Molecular assay  
2.8.2.1 Polymerase chain reaction 
  Polymerase chain reaction is a molecular assay that is characterized by high 
sensitivity and specificity. It’s not only a qualitative assay but a quantitative one as 
well. PCR assay has the ability to discriminate between actively infected and 
recovered patients. The essay is based on quantifying the viral RNA which is known 
as viral load and the results of the assay are expressed in IU per ml [9]. This assay is 
used in monitoring both viral replication and viral clearance by the infected host. This 
in turn is used in diagnosis and assessment of anti-viral therapy efficiency. There are 
several reasons contributing to PCR assay variability for instance: sample handling 
and storage settings, precise design of amplification primers, inconsistent biochemical 
reactions and efficiency of post-amplification detection systems. This means that 
highly controlled quality control procedures should be utilized when performing this 
assay [43]. 
2.8.2.2 Branched DNA assays 
Branched DNA assay is another quantitative assay based on signal 
amplification rather than target amplification; which is the case in PCR assay. This 
technology is based on capturing HCV RNA in a micro-well by hybridization, and 
then measuring the quantity of captured RNA via signal amplification of chemi-
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luminescent produced in response to RNA hybridization. Comparing branched DNA 
assay to PCR, the later has been found to be much more sensitive ruling out false 
negative results in cases of low viremia load. On the other hand results from branched 
DNA assay have been found to be more standardized and reproducible [44]. 
2.8.3 HCV genotype testing 
HCV genotype testing is essential to guide treatment algorithm which involves 
the course of therapy, the period of treatment and the addition of interferon regimen. 
The reference methods fall into two main categories either analyzing points of 
alteration within HCV genome through screening tests or sequence analysis of larger 
segments of HCV genome as in confirmatory testing [43]. 
2.8.4 Assessment of liver disease severity  
2.8.4.1 Invasive technique (Liver biopsy) 
Recent studies have proposed that proper liver disease staging has a major 
therapeutic impact, knowing that liver fibrosis is reversible, in other words it can be 
modified by treatment. Histo-pathological assessment using a biopsy or a surgical 
sample is considered as the “gold standard” or a reference test for the evaluation of 
liver fibrosis .Despite being a gold standard, it is associated with several limitations. 
For instance: being painful, sampling error that leads to improper-estimation of the 
feature being assessed, inter- and intra-observer variation in pathology reporting and 
finally significant mortality and morbidity owing to the invasive nature of the 
technique. With these limitations, noninvasive methods of liver fibrosis assessment 
have been developed [45, 46]. 
2.8.4.2 Non-Invasive techniques 
Alternative to invasive biopsy, non-invasive techniques are frequently utilized 
for liver fibrosis and cirrhosis staging besides clinical findings. These techniques 
include transient elastography (TE) and biomarkers’ detection, that are classified to 
direct and routine serum-based laboratory tests known as indirect biomarkers. Direct 
and indirect biomarkers are listed in (Tables 1). Despite the fact that the level of 
indirect biomarkers is altered in hepatitis, they are not specific. On the other hand, 
direct biomarkers include soluble or secreted proteins that are produced by hepatic 
stellate cells during liver fibrosis. In addition to biomarkers, several scoring 
algorithms are utilized in liver disease staging. These include:  FibroTest, Fibrosis-4 
(FEB-4) and the AST to PLT ratio index (APRI). Despite their ability to diagnose 
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advanced fibrosis (Stage-2), many of these non-invasive techniques cannot distinguish 
between early stages of liver fibrosis [47]. 
2.8.4.3 HCC assessment 
Over four decades ago, alfa feto protein (AFP) which is a serum glycoprotein, 
has been identified as a marker for HCC. Not showing highly elevated levels in all 
HCC cases have made AFP of less accuracy and sensitivity. Another frequently 
utilized tumor marker is Des-gamma-carboxy prothombin (DCP), also known as 
PIVKA II (protein induced by vitamin K absence). On one hand some studies have 
shown 95% sensitivity of DCP, on the other hand other studies have demonstrated its 
poor sensitivity in tumors of size less than 3cm [48]. 
Diagnostic imaging technology is another aspect that plays a crucial role in 
HCC diagnosis. This imaging technology include ultrasonography, computed 
tomography scan (CT scan) and magnetic resonance imaging (MRI). Ultrasonography 
has been widely replaced by CT scans and MRI owing to its low sensitivity. In spite 
of being sensitive, CT scanning is considered to be an invasive technique because of 
the requirement for contrast agent infusion for imaging technique. Magnetic 
resonance imaging have recently became the diagnostic imaging model for HCC in 
different institutions all over the world despite the fact that it might develop some 
allergic reactions in some patients because of the contrast agent. Even with the high 
sensitivity of these imaging techniques, they are considered to be costly. Nowadays, 
research studies is focus on developing ways to improve diagnostic techniques and 
approaches with the intention of identifying earlier stages of HCV mediated HCC 
[48]. 
2.9 Treatment of HCV 
2.9.1 Interferon therapy 
The goal of HCV therapy is to reach a sustained virologic response (SVR). 
SVR is unnoticeable serum HCV RNA 6 months after completing the course of 
therapy. Studies have shown that patients who attain SVR with treatment have less 
than 5% chance of relapse of hepatitis C infection [49]. In early 1960s, steroids were 
firstly used for hepatitis management through regulating ALT levels. On one hand 
this improved the patients’ health, on the other hand later studies have shown that this 
is detrimental and accordingly they were no longer used [7]. In 1991 the US Food and 
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Drug administration (FDA) approved the use of interferon α-2b (IFN- α-2b) for 
chronic hepatitis C management. The mechanism of action of interferon involves 2 
phases; a rapid dose dependent phase followed by a slower one. The first phase 
involves direct inhibition of the viral genome replication while the second phase is 
characterized by an indirect antiviral activity through the stimulation of host mediated 
immune response [50]. Studies have shown that a 24-week course of interferon 
therapy was effective in management of many cases of hepatitis C, even though many 
patients relapsed after treatment because of low SVR rates [51].  
2.9.2 Ribavirin  
Ribavirin is a potential antiviral agent, having broad spectrum of activity and 
acting against both DNA and RNA viruses. It has an inhibitory effect on HCV RNA 
dependent RNA polymerase besides modifying the expression of interferon 
stimulating genes. Antiviral therapy for hepatitis c had been then improved by adding 
ribavirin-based regimens with interferon; SVR rates increased to 38-42% with 
conventional IFN and ribavirin (RBV). Knowing that SVR with interferon (IFN) 
monotherapy was around 6-2% [52]. 
2.9.3 Pegylated IFN-α 
Aiming to improve the pharmacokinetics and dosing regimen of interferon, it 
had been covalently attached to polyethylene glycol (PEG) moiety. This in turn led to 
long-lasting antiviral activity and as a result, patients were given a weekly dose of 
interferon rather than three doses in the same week [52]. Besides on using pegylated 
IFN (peg-IFN) and RBV together the SVR had been elevated to 63% [49]. 
2.9.4 Direct acting antiviral agents 
The launch of direct-acting antiviral agents (DAA) era was in 2011 when the 
two NS3/4A protease inhibitors were introduced and used in combination with 
interferon-based regimens. This era started after the major advances in understanding 
the viral genome and accordingly formulating antiviral agents that targeted the viral 
non-structural proteins and in turn terminating viral replication. The main advantages 
of this new DAA regimens that unlike interferon, they are all administered orally and 
not injections. Besides being highly effective and well tolerated. On average, DAA 
requires only 8-12 weeks of therapy for the majority of patients. Current DAA 
includes NS3-4A protease inhibitors, Nucleotide analogues, Non-nucleoside 
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inhibitors and NS5A inhibitors (Figure 11). [52,53,54] NS-4A protease inhibitors 
include simeprevir, paritaprevir and asunaprevir.  On the other hand, examples of 
NS5A inhibitors are daclatasvir, ledipasvir and omitasvir. Finally, examples of NS5B 
inhibitors are sofosbuvir and dasabuvir and beclabuvir [54]. 
2.10 MicroRNAs biogenesis and regulation 
After their discovery in nematodes “Caenorhabditis elegans” in 1993, 
microRNAs (mi-RNAs) have been found to play an important role in many biological 
processes in plants and animals. MicroRNAs are a family of short non coding RNAs 
that are around 22 nucleotides in length. These non-coding RNAs are too short to 
code for proteins and are thought to control specific genes’ expression via base-
pairing to target messenger RNAs [55]. The first discovered mi-RNA was ln 4-RNA 
that was noticed at the time of its discovery to play an important role in the 
regulation of ln 14-mRNA, causing less expression of proteins from that messenger 
RNA. A huge number of mi-RNAs have been discovered in worms, flies, fish, frogs, 
mammals and plants using different molecular biology approaches such as 
molecular cloning and bioinformatics [56]. 
In humans, mi-RNAs biogenesis starts with a precursor (pri-mi-RNA) that 
folds into a double stranded (dsRNA)-like hairpin structure (Figure 12).  Pri-mi-RNA 
originates either from mi-RNA genes’ transcription by RNA polymerase II or found 
as parts of introns of protein-coding RNA polymerase II transcripts. RNase III type 
endonucleases Drosha (RN3) and Dicer consecutively undergo two step catalysis 
after the hairpin structure formation. The two endonucleases Drosha and Dicer 
always perform their role in association with proteins containing dsRNA-binding 
domains (dsRBDs). The Drosha will partner with DiGeorge syndrome critical region 
gene 8 (DGCR8) in mammals to form Drosha–DGCR8 complex which will then 
convert the pri-mi-RNA to pre-mi-RNA which is a hairpin of about 70-nucleotides. 
The formed Pre-mi-RNAs are subsequently transported from the nucleus to the 
cytoplasm by exportin5, where they encounter Dicer- TRBP complex that lops off the 
loop of the hair pin structure to yield ~20-bp mi-RNA duplexes. The Dicer- TRBP 
complex is formed from the binding of Dicer with TAR RNA binding protein (TRBP) 
in mammals. Following the formation of mi-RNA duplex, one strand of the complex 
formed by the activity of helicase enzyme would be loaded to the Argonaute protein 
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(AGO) to form RNA induced silencing complex (RISC). Some mi-RNA might by 
pass Drosha processing during their formation an example of this case is when the 
primary transcript is an intron that can fold directly to a hair pen structure known as 
Mirtron that would be directly recognized by Dicer [57].   
The formed mi-RNA within the AGO protein will be directed to specific 
mRNA regulating their expression. Mi-RNAs play an important role in post-
transcription gene silencing. They might base pair with specific messenger RNAs 
leading to mRNA decay and translation repression. Other mi-RNAs are key regulators 
in mammalian cells development. Mi-RNAs expression is tightly controlled, each mi-
RNA is having its unique expression pattern. Despite the fact that the same mi-RNA 
might be expressed in several cell types, some mi-RNA are exclusively expressed in 
certain cells [57].   
2.11 Detection of mi-RNAs 
Nowadays mi-RNAs have become significant targets in several research 
fields, because of their potential to be utilized as noninvasive biomarkers. 
Accordingly great efforts have been made to develop efficient and sensitive 
techniques for their detection. Conventional methods include northern blotting, real 
time RT-PCR (qRT-PCR), microarrays and others. Innovative techniques include the 
use of nanoparticle-derived probes, isothermal amplification, electro-chemical 
methods and others. The main difference between the traditional techniques and the 
innovative ones that the latter have higher efficiency of detection by combining a 
multistep signal amplification with some sensitive signal output unit [58].    
2.11.1 Northern blotting for mi-RNA detection 
The expression of both the mature and precursor mi-RNAs have been 
frequently studied using northern blot analysis. Besides enabling quantitation of the 
expression levels of detected mi-RNAs, northern blot analysis allows mi-RNA size 
determination. The technique involves four main steps: First, fractionating RNA 
molecules; a step which is catalyzed using polyacrylamide gel electrophoresis. 
Second, passing on small RNA molecules from the gel onto a membrane. Third, 
Using crosslinking method to fix these small RNA molecules onto the membrane. 
Finally, utilizing radiolabeled oligonucleotide probes for membrane hybridization 
[59]. The main limitation of using northern blotting is the need for radiolabeling 
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which might lead to a contamination, in addition to being complex technique that has 
low sensitivity. The low sensitivity of this technique is attributed to the need of a great 
amount of mi-RNA per sample to be adequately analyzed, which is not the case all the 
time especially when the available sample is cell or tissue [58, 60].   
2.11.2 qRT-PCR for mi-RNA detection 
PCR product real time detection is the main idea of qpcr technique, which is 
considered to be the gold standard for mi-RNA detection. In this approach, all mi-
RNA molecules are firstly reverse transcribed then elongated by an identical tail 
usually a poly A tail used to prime the reverse transcription into a complementary 
DNA (cDNA) [61]. There are several tactics for qpcr normalization, either using a 
normalization gene or what so called a housekeeping gene or adding a synthetic 
spike-in. The most well know housekeeping gene in most of mi-RNA studies is 
RNU6B (U6). However, studies have revealed that the expression of such 
housekeeping genes is not stable among different individuals with different disorders. 
The other approach of using a synthetic spike in which is a synthetic mi-RNA from 
another organism such as Caenorhabditis elegans have shown better normalization 
results [62]. A specific mi-RNA forward and reverse primers are used to form 
multiple copies of the targeted mi-RNA sequence making this method highly sensitive 
and specific for mi-RNA detection [63].   
2.11.3 Microarray for mi-RNAs detection 
Microarray is a technology based on hybridizing the target mi-RNA sequence 
with a complementary probe. The targeted mi-RNA is usually labelled with a 
fluorescent dye and upon binding with the complementary probe it would result in 
fluorescence emission. Recent studies have shown the high biocompatibility of 
nanomaterials toward nucleic acid probes; hence, the use of these materials has shown 
highly improved efficiency and sensitivity. Despite the enhanced efficiency of using 
nanomaterials in mi-RNA detection, the existence of a specialized nanotechnology 
platform is essential for this technique [59, 61].   
2.12 mi-RNAs and HCV infection. 
MicroRNAs have been acknowledged as very important in hepatitis C virus  
infection induced hepatic complications; the alteration in the expression of mi-RNA 
have been reported to be involved in the changes involved with the viral replication 
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[64, 65], translation [66], gene expression [67, 68], and in controlling response to 
interferon (IFN) therapy [69]. 
On one hand some mi-RNAs would regulate HCV translation and replication 
stimulating both processes which is the case in miR-122. On the other hand, other mi-
RNAs would inhibit the viral genome production such as miR-199a* and those 
regulated by interferon beta (IFN-β). This in turn would moderate IFN-mediated 
antiviral response. The expression of miR-155, which enhances the proliferation and 
carcinogenesis of liver cells, was noticed to be induced after the infection with 
hepatitis C virus [70]. Specific mi-RNAs for liver, such as miR-122, miR-155, miR-
125b, miR-16 and miR-34a, are experiencing different expression in the serum of 
HCV infected patients [71, 72].  
2.13 Circulatory mi-RNAs as biomarkers in HCV infection 
Mi-RNAs are essential in screening and diagnosing of hepatitis C infection. 
These small RNA molecules could be either detected within body cells and tissues or 
circulating as extracellular mi-RNA. On one hand, extracellular mi-RNAs are either 
circulating in membrane vesicles with adequate stability towards nuclease activity or 
can be vesicle free and accompanied with either AGO proteins only or transported by 
HDL particles (Figure 13).    On the other hand, these circulating small RNA are 
found in blood plasma, serum, and other body fluids such as; saliva, peritoneal fluid 
urine, breast milk, seminal plasma,  amniotic fluid,  cerebrospinal fluid, and pleural 
fluid [73].  
Extracellular mi-RNA are encapsulated in three kinds of membrane vesicles 
these are: apoptotic bodies, shedding vesicles, and exosomes. Shedding vesicles, and 
exosomes both are known as microvesicles, which are produced by all types of body 
cells, made up of lipid layers and usually enclosing cellular components including 
protein, mRNA and mi-RNA.  Shedding vesicles are created by budding towards the 
outer side and fission of the plasma membrane. Exosomes are much minor membrane 
particles that normally exist within the lumen of multivesicular bodies (MVBs). After 
fusion of (MVBs) with the plasma membrane, exosomes will be released. Apoptotic 
bodies from its name are by products and remaining particles of apoptosis [73, 74, 
75]. 
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A number of latest research have revealed that some circulatory mi-RNA 
(exosomes) can play a crucial role during viral infection in intercellular, immune 
response, tumor progression, and neurological processes. There are two hypothesis 
regarding extracellular mi-RNA secretion into blood circulation. First, these 
circulatory mi-RNA are passively secreted as byproducts of routine microvesicle 
secretion and cell death. Second that they are released specifically to perform a certain 
function such as cell-cell communication [73]. Worth mentioning, the number of 
specific mechanisms for mi-RNA release from the cell are much more than passive 
release means. This in turn strengthens the belief that circulatory mi-RNAs are 
associated with regulatory and pathophysiologic mechanisms [76]. 
Circulatory mi-RNAs expression levels have been recently implicated to 
hepatitis C infection and HCC. For instance; expression levels of miR-134, miR-198, 
miR-320c and miR-483-5p have been found to be up-regulated in the serum HCV 
infected patients of genotypes 1 and 3 [70]. Serum levels of miR-20a and miR-92a in 
HCV infected fibrosis cases were considerably up-regulated compared with that of 
healthy subjects. Subsequently, they can be used as markers of HCV mediated liver 
disease progression [77]. 
Circulatory mi-RNA could be utilized as prognostic biomarkers in cases of 
HCC. Elevated serum levels of miR-122, miR-155 and decreased levels of miR-199a 
have been correlated to HCC pathogenesis. It has been postulated that miR-122 and 
miR-155 are oncogenic mi-RNAs that induce liver carcinogenesis in HCV infected 
patients [78].  
Serum levels of miR-16 and miR-199a were significantly down-regulated in 
HCC than in chronically infected patients or control subjects. In addition to this, miR-
16 has been proposed to be used in association of conventional biomarkers for HCC 
diagnosis [79]. In another study serum levels of miR-19a, miR-195, miR-192, and 
miR-146a have been revealed to have high accuracy in the differentiation between 
healthy controls and HCC affected individuals. Besides being proposed to be utilized 
as a biomarker incases of HCC, miR-19a has been claimed to be used for the study of 
liver prognosis from fibrosis to cirrhosis and finally HCC [80].  
In 2007 a group of researchers in Germany suggested that serum miR-21 level can be 
used as a marker for necro-inflammatory activity, but wouldn’t differentiate between 
HCV and HCV-induced HCC infected patients [81]. MicroRNA-141 and microRNA-
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200a serum levels have been found to be down-regulated in HCC patients compared 
to HCV infected ones, so these 2 mi-RNAs have been proposed to discriminate 
between chronic infection of HCV and HCC [82]. 
2.14 Role of mi-RNA 122 in HCV infection, liver disease and 
metabolism 
2.14.1 Role of mi-RNA 122 in HCV infection 
Besides being one of the firstly discovered tissue specific mi-RNAs, miR-122 
is the most prevalent liver mi-RNA, accounting for nearly 70% of mi-RNA pool in 
hepatocytes. It is released from chromosome 18 in humans. Many researchers are 
interested in studying miR-122 owing to its potential role in HCV replication, 
transcription regulation and translation, HCC and cholesterol metabolism. miR-122 
regulates virus C translation, increasing its’ rate through the interaction with the HCV 
IRES [37].  On one hand, hepatic levels of miR-122 have been found to be higher in 
HCV infected patients of genotype-3 than those of genotype-1. On the other hand, 
serum levels of miR-122 have been found to up-regulated in HCV-1 while in HCV-3 
there has been no correlation between serum and hepatic levels [83].  
In addition to the former roles, miR-122 has been known to play a significant 
role in anti-HCV therapy. Accordingly a pharmaceutical company (Santaris Pharma) 
has developed an anti-viral therapy in the form of antisense oligonucleotide. 
Miravirsen is an antisense oligonucleotide of a complementary sequence to miR-122 
that plays an important role in miR-122 inhibition which subsequently would alter 
viral replication [84].  When the former therapy was targeted to the liver through 
intravenous injection, it effectively inhibits miR-122. A pilot study has been 
performed on four chimpanzees and has given promising results by reducing the viral 
load in these animals effectively and with no toxicity [37]. 
2.14.2 Role of mi-RNA 122 in HCC 
Among the recent advances, miR-122 has been found to be down-regulated in 
cases of HCC compared to normal liver. This down expression is correlated with poor 
prognosis of the cancer which suggests that miR-122 is a tumor suppressor [85]. On 
the other hand, several studies have revealed that the expression level of serum miR-
122 is down-regulated in cases of HCC compared to healthy subjects [86]. 
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2.14.3 Role of mi-RNA 122 in Liver diseases 
Liver injury due to acetaminophen toxicity has induced a noticeable change in 
the expression levels of several mi-RNAs. Among these, miR-122 expression levels 
has been found to be implicated to the dose- and exposure duration of acetaminophen. 
These changes have been observed in the plasma and have been correlated to serum 
aminotransferase levels and the histopathology of liver degeneration. Worth 
mentioning, the changes in miR-122 levels have been detected significantly earlier 
than aminotransferase levels. These findings propose the possibility of utilizing miR-
122 as sensitive biomarkers for drug-induced liver injury [87, 88]. 
2.14.4 Role of mi-RNA 122 in cholesterol metabolism and iron 
homeostasis 
miR-122 has been found to play an important role in cholesterol metabolism 
and systemic iron homeostasis. On one hand, the mechanism by which miR-122 
regulate cholesterol metabolism is not yet established. On the other hand, miR-122 
control systemic iron homeostasis by acting upon the target mRNAs hemochromatosis 
(Hfe) and hemojuvelin (Hjv). These mRNAs are translated to activators of the 
hormone hepcidin, which standardize iron availability. Studies have shown that mice 
with reduced miR-122 expression experience iron deficiency [37]. 
2.15 Role of mi-RNA 155 in HCV infection and liver disease 
2.15.1 Role of mi-RNA 155 in immune response 
Recent advances in mi-RNA studies have focused on miR-155, an immune 
system mi-RNA. In human, miR-155 is found at a region within chromosome 21q21.3 
known as B cell integration cluster (BIC) [89]. When correctly regulated, this mi-
RNA is found to play an important role in protective immunity. While when 
dysregulated, it may contribute to malignant conditions [90]. Studies have shown that 
miR-155 directly induced interferon stimulating genes (ISG) expression in 
macrophages and stimulate a direct antiviral response in mRNA HCV replicon [91].   
2.15.2 Role of mi-RNA 155 in HCV infection 
Hepatic miR-155 expression was significantly up-regulated in serum of HCV-
infected patients [92, 93].   Chronic HCV subjects that haven’t started any therapeutic 
regimen were shown to have higher expression of miR-155 in their circulating 
monocytes when evaluated against people who cleared HCV infection after therapy. 
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This finding hypothesized a potential correlation between elevated miR-155 in 
monocytes and HCV viral existence and/or replication [90, 92].  In 2013, a study in 
China has postulated that miR-155 plays a crucial role in hepatic fibrosis through the 
regulation of the pathological network involved in fibrosis process. These findings 
suggest the role of miR-155 in the pathogenesis and progression of chronic HCV 
infection to HCV-induced HCC [94].  Moreover, miR-155 expression levels were 
increased in serum, liver tissues, and peripheral blood mono nuclear cells (PBMCs) of 
genotypes 1, 2 and 3 HCV-infected patients [92, 93].  Conversely, in another study it 
was reported that miR-155 expression did not change in the PBMCs of Egyptian 
patients genotype 4 with chronic infection of HCV when being evaluated against 
healthy subjects [95].   
2.15.3 Role of mi-RNA 155 in HCC 
It is consistently postulated that miR-155 acts as an oncogenic mi-RNA 
(oncomiR) in human tumors. This notion is based on the evidence that this mi-RNA 
expression has been reported to be increased in several human cancers. In hepatitis C 
infected patients, miR-155 levels were found to be significantly up-regulated, in 
addition to fostering liver cells proliferation and carcenogenesis by modulating Wnt 
signaling. The former pathway plays a vital role in the regulation of cell apoptosis and 
proliferation. [93]. A study in Shanghai had postulated that miR-155 can be used as a 
powerful biomarker for cancer relapse and survival of HCC patients following 
orthotopic liver transplantation (OLT). This hypothesis was reached after finding that 
the expression of miR-155 was higher in tumor tissues in patients with post-OLT 
HCC relapse compared with those in patients with non-recurrence [96]. 
2.16 Role of mi-RNA 21in HCV infection and liver disease. 
2.16.1 Role of mi-RNA 21 in HCV infection 
A study published in 2013 has studied the role of miR-21 during HCV 
infection. The results of this study revealed that miR-21 suppresses triggered type I 
IFN production in hepatocytes of HCV transfected Huh7 cell line. Besides, it 
proposed that miR-21 enhances HCV replication as well as facilitating the replication 
of other viruses by reducing antiviral activity of IFN-α. This study pointed out that 
miR-21 controls the expression of components of the Toll-like receptor signaling 
cascade too [97]. A study performed in Germany compared the expression levels of 
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miR-21 in serum of healthy controls, chronically infected HCV, cirrhosis and HCC 
patients. The results revealed that miR-21 expression is up-regulated in chronic 
hepatitis C patients (CHC). Moreover this study reported that the expression levels of 
miR-21 wasn’t different between patients with cirrhosis and HCC [81]. Plasma levels 
of miR-21 wasn’t different between HCV induced cirrhosis and HCC. On the other 
hand, compared to healthy volunteers and CHC, miR-21 is highly expresses in HCC 
[98]. 
2.16.2 Role of mi-RNA 21 in HCC  
Recent studies have revealed that miR-21 expression levels is altered in 
multiple types of cancers among these is HCC. miR-21 had been found to be up-
regulated in HCC compared to normal liver tissue. The increased expression of miR-
21 has been associated with malignant cell proliferation, invasion and metastasis. In 
addition, it plays an important role in cellular transformation via suppression of 
apoptotic signaling which support the hypothesis that miR-21 acts as an onco-miR 
[78, 99, 100]. A study in China had demonstrated that serum miR-21 is elevated in 
patients with HCC or chronic hepatitis and hypothesized that miR-21 can act as a 
novel biomarkers for liver injury generally and not particularly for HCC [81, 101]. On 
the other hand, another study made on Egyptian patients of genotype 4 had revealed 
that miR-21 is overexpressed in sera of HCC patients compared to patients with 
chronic hepatitis [78]. 
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Chapter 3 SUBJECTS AND METHODS 
3.1 Subjects 
This study was performed after receiving IRB approval from the American 
University in Cairo CASE #2015-2016-185 and the approval of the National 
Hepatology and Tropical Medicine Research Institute (NHTMRI) in Cairo serial No: 
10-2016.  
Thirty seven Egyptian patients with chronic hepatitis C (CHC), 39 Egyptian 
patients with hepatitis C induced cirrhosis, 40 Egyptian patients with hepatitis C 
induced hepatocellular carcinoma (HCC) and 40 healthy controls were included in 
this study. CHC patients (male=26, female=11, mean age=45±9.64; range: 25-64). 
Cirrhotic patients (male=20, female=19, mean age=57± 5.65; range: 43-76). HCC 
patients (male=23, female=17, mean age=60 ± 7.69; range: 41-75).  
All diseased patients were having HCV positive antigen and were genotype 4. 
Anti-HCV antibody assessment, viral load and genotyping were performed using real 
time pcr assay.   
 Patients were excluded from the study if they had hepatitis B virus (HBV) 
antigen or antibody, human immune deficiency virus (HIV) infection. Additionally, in 
cases of HCC patients, they were excluded if they had started a chemotherapy 
regimen or had undergone a surgical operation.  
A total of 40 healthy control participated in this study (male=24, female=16, 
mean age=47 ± 10.51; range: 21-65). None of the samples were known to be having a 
history of hepatic disorder and all of them had normal liver function tests and negative 
serological findings for viral liver diseases. 
3.1.1 Laboratory assays 
Samples were gathered from National Hepatology and Tropical Medicine 
Research Institute Hospital, Cairo. For healthy control patients, samples were 
collected at the Biochemistry lab at the British University in Egypt from healthy 
volunteers. Written informed consent was obtained from all patient and healthy 
population. Whole blood was collected from patients and control and plasma was 
29 
separated for routine assessment. The later included whole blood picture, HCV 
qualitative assay and liver function tests; alanine amino transferase (ALT), aspartate 
amino transferase (AST), alkaline phosphatase (ALP), direct bilirubin, albumin, 
prothrombin time, platelets’ count and leukocytes’ count using commercially 
available kits. A portion of the plasma was separated and stored at -80 ºC until 
molecular assays.  
3.1.2 Histological investigations and assessment of fibrosis, cirrhosis 
and HCC 
In viral hepatitis C infected patients, CT-abdominal ultrasonography and liver 
biopsy were done to determine the stage of fibrosis using Metavir scoring system in 
which F= fibrosis (F0= no fibrosis, F1= portal fibrosis without septa, F2= portal 
fibrosis with rare septa, F3= numerous septa without cirrhosis, and F4= cirrhosis) 
[102]. In addition to the former tests, magnetic resonance imaging (MRI), RBC, 
bleeding profile (Prothrombin time (PT) and International Normalized Ratio (INR)) 
creatinine, urea, viral load, hemoglobin, hemoglibinA1C, Packed cell volume, mean 
corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin 
concentration, red blood cells’ distribution width, alfa feto protein (AFP) assessment 
was achieved in cases of CHC, cirrhosis and HCC. Barcelona-Clínic Liver Cancer 
(BCLC) assessment was utilized to determine HCC staging in which (A= early stage, 
B=intermediate stage, C=moderate stage, D=terminal stage). Eight HCC patients were 
diagnosed to be in an early stage, 12 patients were intermediate stage, 12 patients 
were moderate stage and 8 patients were in terminal stage. 
3.2 Plasma microRNA assay 
3.2.1 RNA extraction  
To separate the plasma, blood samples were centrifuged using bench-top 
centrifuge (EBA 20, Hettich, Germany) at 4000rpm for 10mins. To completely 
remove cellular components, the supernatant was separated and centrifuged at 
13000rpm using a cooling centrifuge (Pro-Research, Centurion scientific, UK) at 4ºC 
for 10mins.  
Total RNA including mi-RNAs’ extraction was performed using Direct-zol™ RNA 
MiniPrep (cat. no. R2050, Zymo Research, USA) according to the protocol provided 
by the manufacturer which involved lysis using trizol reagent TRI Reagent® then 
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washing of the lysate in a spin column; the Zymo-Spin™ IIC Column. Briefly, 3 
times’ plasma volume (600 µl) of TRI Reagent® (cat. no: R2050-1-50) was added to 
the plasma volume (200 µl) to disrupt proteins and plasma components while 
maintaining RNA integrity. The mixture was mixed well by vortexing for 2mins and 
then incubated for 5mins at room temperature. To remove the particulates, the mixture 
was centrifuged at 13000 rpm for 1min using cooling centrifuge (Pro-Research, 
centurion scientific, USA). Following this step, synthetic 3.75µl (25 fmol) 
Caenorhabditis elegans miR-39 (cel-miR-39) was spiked in the supernatant of 
sample TRI homogenate. One and half volume ethanol was then added to and mixed 
well by vortexing for 2mins. miR-39 was selected as a reference owing to the absence 
of any similarity between its’ sequence and human mi-RNAs and being not changed 
by any diseases which is the case in housekeeping genes [103, 104].  The mixture was 
then loaded into Zymo-Spin™ IIC Column and centrifuged at 13000rpm for 1min. 
The column was then transferred to a new collection tube and 400µl of Direct-zol™ 
pre-wash Buffer were added to the column and the column was centrifuged at 
13000rpm for 1min. The former step was repeated twice then 700µl of RNA wash 
buffer were added to the column and centrifuged at 13000rpm for 1min. The column 
was then centrifuged in an emptied collection tube for additional 2mins. RNA and mi-
RNAs were then eluted using DNase/RNase free water. Various elution 
volumes/methods have been tested for 10x dilution of synthetic miR-39 (100pg/ µl), 
for optimization purposes, using either 1X50µl, 2x25µl or 3x16.5µl DNase/RNase 
free water. The quality and quantity of extracted RNA was determined using 
Nanodrop (Q5000 UV-Vis Spectrophotometer, Quawell, USA) through measurement 
of A260/A280 ratio. 
3.2.2 Poly Adenylation  
Poly Adenylation was carried out on 100ng of total extracted RNA using E. 
coli Poly (A) Polymerase | NEB (New England Biolabs). The former step was firstly 
optimized trying different concentrations of total extracted RNA as an input (50, 100, 
250 and 500 ng). The reaction mixture volume was 10μl and prepared by mixing a 
volume of extracted RNA equivalent to 100ng concentration with 1μl of E. coli Poly 
(A) Polymerase. Reaction Buffer, 1μl (5mM) ATP, 0.2μl E. coli Poly (A) Polymerase 
and Dnase/Rnase free water. The reaction was incubated at a dry bath incubator 
(Boeco, Germany) at 37ºC for 30mins.   
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3.2.3 Reverse transcription  
Reverse transcription (RT) was carried out on 4μl of poly adenylated RNA 
using GoScript Reverse Transcription (Cat. no.A5001, Promega, USA). The reaction 
mixture volume was 20μl and prepared by mixing 4μl of poly adenylated RNA with 1 
μl (20pmole) gene specific primer. The reaction was then placed into a dry bath 
incubator at 70 ºC for 5mins. Then immediately the reaction was chilled in ice-water 
for at least 5mins. Another tube of reverse transcription was prepared by adding 4μl 
GoScript™ 5X Reaction Buffer, 4μl MgCl (5mM), 1μl PCR Nucleotide Mix (0.5mM 
each dNTP), 1μl Recombinant RNasin®Ribonuclease Inhibitor, 1μl GoScript™ 
Reverse Transcriptase and 4μl Dnase/Rnase free water. The two reaction tubes were 
then added to each other and then were incubated at 25 ºC for 5mins for annealing. To 
allow strand extension, the reaction tube was then incubated at 42 ºC for 60mins. 
Finally for reaction inactivation, the reaction was incubated at 70 ºC for 15mins. 
3.2.4 Quantitative real-time PCR 
Real-time pcr was firstly carried out on 2μl of either stock, 2.5x, 5x or 10x 
dilution of cDNA obtained from reverse transcription step using Gotaq qpcr master 
mix (Cat. no.A6001, Promega, USA). The master mix includes a SYBR® Green I like 
fluorescent DNA-binding dye that presents excessive fluorescence enhancement when 
it binds to double-stranded DNA (dsDNA). The reaction mixture volume was 20μl 
and prepared by mixing 2μl of cDNA with 0.8μl (0.4μmol) gene specific forward 
primer and 0.8μl (0.4μmol) of gene specific reverse primer, 0.2μl carboxy-X-
rhodamine (CXR) reference dye, 10μl master mix and 4.2μl Dnase free water. To 
ensure that taq polymerase enzyme is not having a reverse transcriptase activity, a 
trial was performed on a prepared poly adenylated miR-39 without adding reverse 
transcriptase enzyme in the RT-step. The amplification plot of this step gave 
undetectable Ct, this result ensured that taq-polymerase catalyze PCR without having 
reverse transcriptase activity. The mi-RNA-specific primers are  designed by 
Dr.Abdullah Gibriel depending on miRNA sequences obtained from the miR-Base 
database (http://www.mirbase.org/) and he has the proprietary right for the sequence. 
The annealing temperatures of the 3 selected miRNAs in addition to miR-39 were 
optimized at different temperatures (50 ºC, 55 ºC, 60 ºC, 65 ºC, 70 ºC and   75 ºC). 
The reaction was then placed into real-time PCR system (Applied Biosystems, 
Thermo Fisher Scientific, Singapore). The instrument was operated with the following 
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conditions: 95 ºC for 2mins for activation followed by 95 ºC for 5secs denaturation 
then 60 ºC for 30secs for annealing step and finally 72 ºC for 20secs for extension. 
The device was adjusted to perform 50 cycles of the previous conditions followed by 
running a melt curve. 
3.3 Data analysis 
The results of the real-time PCR system is expressed in term of cycle 
threshold (Ct), which is the number of cycles needed for the fluorescent signal to 
cross the automated threshold. First, ∆Ct was estimated by subtracting the Ct value of 
mi-RNA-39 from the Ct of each targeted mi-RNA for the same sample. Then ∆∆Ct 
was calculated by subtracting the mean ∆Ct of the reference group (Chronic HCV 
infected category) from ∆Ct of each sample for each mi-RNA.  
∆∆Ct of each mi-RNA= [for each sample (Ct target mi-RNA- Ct miR-39) – mean (Ct 
target mi-RNA- Ct miR-39) of the reference group] [105]. 
This is then followed by calculating the fold change, which is equal to 2-ΔΔCT (2 to 
the power of minus Delta Delta CT). Then transforming 2-∆∆Ct to log2 fold change. 
The value of log2 ≥0.5 or ≤−0.5, were considered as notable differentially 
expressions.  
3.4 Statistical analysis 
Supplementary comparisons were carried out between HCC group and Non-
HCC (Control, CH and cirrhosis). Quantitative values were expressed by mean ± SE. 
They were compared by one way anova (ANOVA), post hoc test and chi-square test 
when appropriate with P value ≤ 0.05 is considered significant. Pearson correlation 
was used to study the correlation between studied mi-RNAs in each category. 
Receiver operator characteristic (ROC) curves were drawn to investigate the accuracy 
and area under the curve (AUC) was calculated. All statistical analysis were done 
using computer program Statistical Package for the Social Sciences (SPSS, Chicago, 
IL, USA) software 15 and MedCalc (MedCalc Software, Ostend, Belgium) version 
15.0 for Microsoft Windows. 
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Chapter 4 RESULTS 
4.1 Demographic data and clinical features of study subjects 
Demographic and clinical data records are summarized in (Tables 2, 3) and 
(Figures 14-29). There was no significant differences in gender distribution among 
the four groups (P=0.4622). Cirrhotic and HCC patients had significant increased 
levels in ALT (P=0.042 and P<0.0001 respectively) and AST (P=0.03 and P<0.0001 
respectively) compared to healthy control. However, elevated levels of ALT and AST 
appeared to non-significant in CHC patients compared to healthy control (P=0.124 
and P=0.513 respectively). ALP and total bilirubin levels were significantly elevated 
among the three diseased groups compared to healthy control subjects (P<0.0001, 
P=0.004 respectively). On the other hand, Albumin was significantly reduced in the 
three diseased groups compared to healthy control (P<0.0001). There was no 
significant difference in prothrombin time between the four categories (P=0.108). 
However, Total leukocyte and platelet counts appeared to be significantly deregulated 
among the four categories (P=0.014, P=0.004 respectively).  
There were no significant differences in creatinine, HBA1C, MCV, MCH, 
MCHC, RDW, AFP and log10-viral load among the cirrhotic (P=0.956, P=0.999 
respectively) and HCC groups (P=0.790, P=0.276 respectively) when compared to 
CHC. However, hemoglobin, RBC’s levels and PCV were significantly dysregulated 
among the three diseased categories (P<0.0001, P=0.001 and P<0.0001 respectively). 
There had been a marginal significance in urea levels between the three diseased 
groups ( P=0.042) 
4.2 Optimization steps 
Several trials had been made on pure synthetic miRNA (mir-39) sample 
dissolved in DNase/RNase free water to optimize all our study steps and to ensure 
obtaining the most optimum results. Extraction step had been optimized using 
different volumes of DNase/RNase free water as shown in (Table 4). Elution with 
50μl for one time yielded 16.1% with purity of 2.147. However, when the same 
column was eluted for a second time with 50μl, the yield was 5.56% with purity of 
1.706, to have a total yield of these two steps= 21.66%. On the other hand, when a 
new column was eluted three times with 25μl, the first two times yielded 14% with 
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purity= 1.969. While the third time elution yielded 27.5% with purity=1.493, to have 
a total yield for the three steps= 41.5%. Finally when a new column was eluted four 
times with 16.5μl, the first three times yielded 132.68% with purity=1.642. Yet, the 
last elution yielded 3.5% with purity=1.655, to have a total yield for the four 
steps=136.18%. Our results revealed that eluting the column with 16.5μl of 
Dnase/Rnase free water for three times would enable the elution of most (132.68%) of 
the RNA attached to the column with A260/A280 value of (1.642).  
Furthermore, our results (Table 5) indicated that plasma had a high content of 
mi-RNA (33.5 ng/μl±0.9), yet of low purity (0.9) because of the protein components. 
This was obvious in the difference in purity measured for optimized samples that 
were processed in Dnase/Rnase free water that yielded (purity=1.67±0.01) and the 
actual plasma samples (purity=0.9). These results are in agreement with the data 
supplied by Liping Wang et al. [106] and   Inés Moret et al. [107] that pointed out that 
several mi-RNA plasma extraction practices gave rise to low 260/280 ratios around 1. 
Real time pcr data analysis of the extracted samples with high yield and relatively low 
purity had given cycle threshold at comparable and dynamic ranges, verifying that we 
could progress to polyadenylation step with this yield and purity. 
When we reached the poly adenylation step, serial concentrations (50ng, 
100ng, 250ng, 500ng) as shown in (Table 6) had been tested to investigate the 
optimum concentration of total extracted RNA that would be sensitive at the lowest 
cycle threshold value. Data indicated that there hadn’t be a significant difference in 
Cts of (100ng, 250ng and 500ng) that gave (27.67, 27.74 and 27.92 respectively). 
These results indicated that the enzyme saturates after utilizing a concentration of 
100ng. However, utilizing 50ng gave a large Ct of 30.1. Our results indicated that the 
utilization of 100ng of total extracted RNA in poly-adenylation step is considered to 
be the optimum concentration (Figures 30).  
Regarding the RT-qPCR optimization, several dilutions were tested (stock, 
2.5x dilution, 5x dilution and 10x dilution) as shown in (Table 7). The cycle threshold 
obtained for stock, 2.5x, 5x and 10x was 23.56, 23.65, 22.94, and 23.7 respectively. 
Our data revealed that utilizing 2μl of 5x dilution of cDNA would be the optimum 
choice (Figures 31). Despite the fact that the four trials gave an acceptable dynamic 
and comparable Ct, but we didn’t select a high concentration owing to the fact that the 
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extracted plasma samples contain PCR inhibitors [108]. Besides highly diluted 
samples would not have enabled us to detect mi-RNAs in samples if present in very 
low concentrations. 
Moreover, the best annealing temperature (Table 8) was selected after 
performing RT qPCR for the 4 miRNAs (miR-39, miR-122, miR-21 and miR-155) at 
different temperatures (50ºC, 55ºC, 60ºC, 65ºC and 70ºC). miR-39 gave (22.67, 23.1, 
25.66, 30.96 and undetected Ct) at (50ºC, 55ºC, 60ºC, 65ºC and 70ºC respectively) 
(Figures 32). miR-122 gave (33.1, 32.31, 34.26, 39.98 and undetected Ct) at (50ºC, 
55ºC, 60ºC, 65ºC and 70ºC respectively) (Figures 33). miR-21 gave (27.19, 
28.15,33.92, 41.86and undetected Ct) at (50ºC, 55ºC, 60ºC, 65ºC and 70ºC 
respectively) (Figures 34). miR-155 gave (38.93, 42.17, undetected, and undetected 
Ct) at (50ºC, 55ºC, 60ºC, 65ºC and 70ºC respectively) (Figures 35). Our results have 
demonstrated that 50 ºC is the optimum annealing temperature for all miRNAs as it 
gave the lowest Ct value at comparable and dynamic range with a single peak upon 
performing melt curve analysis. 
4.3 Differential expression of plasma mi-RNAs in healthy controls, 
Cirrhotic subjects and HCC patients 
Plasma mi-RNA profiles of miR-122, miR-155 and miR-21 were analyzed in 
healthy control, cirrhotic and HCC patients compared to chronic hepatitis C patients 
(Table 9). The mean levels of mi-R-122 were significantly dysregulated (P<0.0001) 
in healthy control, cirrhotic and HCC group compared to CHC with log2 fold change= 
(0.88±0.65 vs 0.00±0.57 vs 5.45±1.31, log2 fold change± standard error) (Figures 
36). Noting that log2 fold scale increase is equivalent to 32x increase in linear scale. 
Interestingly, miR-122 was significantly up-regulated in HCC patients compared to 
healthy controls and cirrhotic subjects (P=0.002 and P<0.0001, respectively). The 
log2 fold down regulation in cirrhotic group compared to healthy control was non-
significant (P=0.772). 
The mean levels of mi-R-21 were significantly dysregulated (P=0.005) in 
healthy control, cirrhotic and HCC group compared to CHC with log2 fold change= 
(3.52±1.07 vs 0.88±0.90 vs 6±1.08, log2 fold change± standard error, respectively) 
(Figures 37). However, miR-21 was significantly up-regulated in HCC patients 
compared to cirrhotic patients with Log2 fold change of 6 (p=0.03) (which is 
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equivalent to 64 times linear increase) but not compared to healthy control (P=0.093). 
Although Control and HCC in mir-21 increased by 3.52 and 6 log2 scale they were in 
marginal insignificance (p=0.093) that might be due to limited number of samples 
used in this study. 
  The mean level of miR-155 was non-significantly (P=0.064) dysregulated in 
healthy control, cirrhotic and HCC group compared to CHC (4.12±1.13 vs -2.42±0.93 
vs 2.72±0.96, log2 fold change± standard error, respectively) (Figures 38). 
4.4 Evaluation of mi-RNAs as potential diagnostic markers 
ROC curves (Table 10) and (Figures 39, 40) were conducted and the results 
revealed that miR-122 differentiated HCC patients from healthy control and cirrhotic 
patients with an AUC of 0.705 (P=0.002) and 0.767 (P <0.0001) respectively. The 
best specificity and sensitivity to differentiate HCC from control were 57.50% and 
65.52% (at a cutoff >1.86, positive predictive value=52.75%, negative predictive 
value=57.15%, likelihood ratio positive (LR+) = 1.3 and likelihood ratio negative 
(LR−) = 0.6)). The best specificity and sensitivity to differentiate cirrhotic from HCC 
patients were and 61.54% and 71.43% (at a cutoff> 0.43, positive predictive 
value=57.15%, negative predictive value=75%, LR+ =1.83 and LR− = 0.464) to 
discriminate cirrhotic patients from HCC subjects.  
Additionally, analyzing ROC curve (Table 11) and (Figures 41) indicated that 
miR-21 differentiated HCC patients from cirrhotic patients with AUC of 0.767 
(P<0.0001). The best sensitivity and specificity to differentiate HCC patients from 
cirrhotic were 72.97% and 50% (at a cutoff >-0.43, positive predictive value=65.9%, 
negative predictive value=58.3% LR+ =1.4 and LR− = 0.54).  
4.5 Correlations between studied mi-RNAs in healthy control, 
cirrhotic patients and HCC subjects 
Correlation between plasma levels of the selected mi-RNAs were examined in 
healthy control, cirrhotic and HCC subjects using Pearson correlation (Tables 12-14). 
Correlation is considered significant if P≤0.05.On one hand, in healthy control 
subjects a correlation was found only between miR-122 and miR-155 (r=0.472, 
P=0.020). On the other hand, no correlation between studied mi-RNAs were found in 
the cirrhotic group. However, in HCC group, several significant positive correlations 
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were found between the tested mi-RNAs. miR-122 was correlated with miR-21 
(r=0.789, P<0.0001), miR-122 was correlated with miR-155 (r=0.681, P=0.004) and  
miR-21 was correlated with miR- 155 (r=0.684, P=0.05).  
4.6 Logistic regression analysis of the three miRNAs combination  
Logistic regression analysis was performed to assess the diagnostic power of 
combing mi-RNAs to differentiate between healthy control and HCC subjects (Table 
15), cirrhotic and HCC patients (Table 16) and healthy control and cirrhotic patients 
(Table 17). Results revealed that combining the three mi-RNAs to differentiate 
healthy control from HCC subjects would relatively increase the AUC to a value of 
0.723 (P=0.049) compared to an AUC=0.705 (P=0.002) upon utilizing miR-122 as a 
standalone biomarker. On the other hand, combining two mi-RNAs (miR-122 and 
miR-21) to differentiate cirrhotic patients from HCC subjects would relatively 
increase the AUC to a value of 0.809 (P<0.0001). Interestingly, logistic regression 
data analysis revealed that combining the three mi-RNAs may have a promising 
diagnostic potential to differentiate healthy control from cirrhotic subjects with AUC 
of value 0.922 (P=0.0007).     
4.7 Correlation between plasma mi-RNAs and clinical data in 
Cirrhotic and HCC patients 
Correlations between alfa feto protein levels and mi-RNA levels were 
examined in cirrhotic and HCC groups. No significant correlation between the studied 
mi-RNAs and AFP levels in cirrhotic group. Interestingly, in HCC group, several 
significant correlations were found between AFP levels and each studied mi-RNA. 
Plasma miR-122 was significantly correlated with AFP levels (r=0.572, P=0.026) in 
the positive direction (Figures 42-A). There was a significant positive correlation 
between plasma miR-21 and AFP levels (r=0.556, P=0.036) (Figures 42-B). Plasma 
miR-155 was positively correlated with AFP (r=0.993, P=0.002) (Figures 42-C). 
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Chapter 5 DISCUSSION 
Hepatitis C virus (HCV) infection is a devastating health challenge that affects 
more than 185 million individuals globally [6].  Unresolved chronic HCV infection 
could develop to more worsening stages such as cirrhosis and/or HCC. The latter is 
the fifth most common cancer that leads to death between men [109].    The lack of 
reliable biomarkers for HCC early diagnosis and prognosis is a current challenge that 
quest the finding of new sensitive and specific diagnostic tools.  
Egypt has the top-most incidence for chronic HCV infection worldwide [110].   
This fact made our decision in selecting genotype4 to be investigated in our study. All 
enrolled patients were genotype4 with detectable HCV RNA viral load and anti-HCV 
antibody positive results. Our demographic data analysis indicated that ALP and total 
bilirubin levels are significantly elevated in all three diseased categories; chronic 
hepatitis, cirrhosis and HCC compared to healthy control. On the other hand, albumin 
levels were significantly reduced in the all three diseased categories compared to 
healthy control. Creatinine, urea and viral load data indicated that there had been no 
significant difference in their levels between the three diseased categories. There 
hadn’t been significant difference in AFP levels among the three diseased categories 
which confirm the results of Di Bisceglie et al. that AFP levels are elevated in 
advanced CHC and that serum AFP values are frequently elevated, even in the 
nonexistence of HCC [110]. This as well confirm the idea that AFP is lacking 
specificity [2, 110].        
Recent studies have shed light on miRNAs and their role in different hepatological 
disorders. Studies have revealed the important role of these short sequenced miRNA 
in different clinical conditions including protein regulation, liver cells’ apoptosis and 
hepatic carcinogenesis through the regulation of oncogenes’ transcription factors and 
tumor suppressor genes [111]. Besides, researches have revealed their role in 
obstructive jaundice [112] and hepatic stellate cells fibrosis [113]. 
The main goal of our study was to investigate the expression of plasma miR-
122, miR-155 and miR-21 as potential and reliable non-invasive biomarkers that can 
differentiate between different stages of HCV infection in Egyptian population and 
used as a sensitive and specific biomarker for HCC. Our data revealed that miR-122 
results and miR-21 are significantly des-regulated among the four selected categories; 
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healthy control, CHC, cirrhosis and HCC. However, miR-155 was des-regulated but 
with non-significance. 
Analysis of miR-122 expression have demonstrated significant fold increase in 
plasma expression level in HCC group compared to healthy control, CHC and 
cirrhosis.  This result coincides with previous studies showing up-regulation in miR-
122 in HCC [101, 114, 115]. The up-regulation of miR-122 may be attributed to its’ 
induction with severe hepatocytes’ injury in cases of HCC [116]. However, in other 
studies miR-122 was down-regulated in HCC human tissue and cell lines 
[117,118,119,120]. This conflict in results may be attributed to the leakage of miR-
122 from the injured liver cells to the blood stream. As a result elevating miR-122in 
serum and plasma and reducing miR-122 levels in human tissue [116].  Another 
conflicting study have demonstrated that miR-122 levels were non-significantly 
down-regulated in human serum compared to healthy control [120]. The discrepancy 
between the results of our study and this study might be due to multiple reasons; first 
the difference in samples used; plasma vs serum samples. Second this might be due to 
the use of a different normalizer which is RNU48 in that case not synthetic miR-39 as 
the one used in our study. There has been conflicting issues concerning the use of 
proper normalizers such as housekeeping genes, small nucleolar rna SNORD, 
RNU48, etc [104].The miRNA length is very short and should not be normalized to 
large RNA such as housekeeping gene. Even SNORD and RNU48 are not favored 
anymore for normalization as their expression have been reportedly to be affected 
with various disease conditions and not to be stably expressed [121]. Moreover this 
might be due to using different reference group which is healthy control in that case. 
Fourthly, this could be due to different etiology and origin of HCC cases as they 
might arise from various HCV genotypes that could have different molecular 
pathogenesis [122,123].  
In addition, the fold change of miR-122 had been shown to be non-significant 
in cirrhotic stage compared to healthy control. Yet, this result was different from 
another study made on 75 HCV chronically affected patients; 25 were CHC, 25 were 
cirrhotic and 25 were HCC that had demonstrated significant down regulation in 
cirrhotic samples compared to healthy group [124]. Again this might be attributed to 
the factors listed above or due to lack of representative number of samples in that 
study. Another study had pointed out that miR-122 expression levels are 
downregulated in late fibrotic stages in mice liver biopsies [125]. On the other hand, 
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our results have demonstrated significant up regulation in HCC samples compared to 
cirrhotic patients. This comes in agreement with several studies that have shown 
significant elevated levels in miR-122 in HCC compared to cirrhotic group 
[116,124,126]. Besides an Egyptian study performed on serum samples came in 
confirmation of these results [115].  In contrast to our results, the study of Köberele et 
al. have demonstrated non-significant elevation in serum miR-122 expression levels 
in HCC group compared to cirrhotic patients [127]. The inconsistency in cirrhotic 
result might be attributed to large ethnic and geographic variability in the prevalence 
of HCC and cirrhosis between the different populations. In addition to the difference 
in samples investigated in our study and other studies.  
Regarding the diagnostic performance of miR-122 in HCC. Our results 
revealed that miR-122 was having a good diagnostic power to differentiate HCC 
patients from healthy control subjects with (AUC=0.705), sensitivity=65.52% and 
specificity=57.50%. Besides having a good diagnostic power differentiating HCC 
patients from cirrhotic patients with (AUC=0.767), sensitivity=71.43% and 
specificity=61.54%. This comes in agreement with the results obtained from Jian Xu 
et al. confirming that ROC curve results obtained from miR-122 expression could 
discriminated between HCC and healthy control and those suffering from chronic 
hepatitis [101].  The former study has shown ROC analysis with (AUC= 0.79), 
sensitivity=71% and specificity=86%. An Egyptian study had partially agreed with 
our results, revealing that serum miR-122 have a good diagnostic accuracy in 
differentiating HCC patients from healthy control with (AUC=0.617) [115]. The 
previous data in addition to knowing that miR-122 is a liver specific mi-RNA would 
make miR-122 a very promising diagnostic marker for HCC. All miR-122 studies are 
listed in  (Table 18). 
Des-regulation of miR-21 had been found to play an important role in different 
malignancies. The former include up-regulation in tissue [128] and serum levels [129] 
in large B-cells lymphoma. Besides being up-regulated in tissue in case of 
glioblastoma tumor [119, 120]. Moreover, miR-21 experiences up-regulation in cases 
of breast cancer [130], colon, lung, pancreas, prostate, stomach [131] pancreatic 
cancer and adenocarcinomas [132]. 
 The present study demonstrated up-regulation in miR-21 expression levels in 
HCC patients compared to cirrhotic patients and also in comparison to healthy control 
group. This upregulation was reported to be significant in comparison to cirrhotic 
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group with a p-value of (0.005). This upregulation was found to be of marginal 
insignificance when compared to healthy control group with a p-value of (0.093). This 
coincides with several studies that have shown elevated expression levels of miR-21 
in HCC plasma [98, 101] and tissue [99, 119]. Additionally our results are in partial 
agreement with an Egyptian study carried on three groups; healthy control, CHC and 
HCC [133]. Their data revealed that miR-21 is significantly up-regulated in HCC 
plasma samples compared to CHC which involved cirrhotic samples which is the case 
in our study. On the other hand, their data demonstrated significant elevation in 
plasma miR-21 expression in HCC compared to healthy control which is contrary to 
our results that have shown up-regulated levels but with a marginal non-significance 
values. Furthermore, our data were contradicted with Verena Bihrer et al. who have 
demonstrated that miR-21 up-regulation levels in HCC tissues and plasma weren’t 
significant compared to CHC samples of German patients [83]. Noting that the 
previously mentioned study has involved chronic hepatitis and HCC patients of 
different etiologies. 
Our results have shown down-regulation in miR-21 expression levels in CHC 
and non-significant decrease in the expression levels of cirrhotic patients compared to 
healthy control. In contrast to our results, several studies have demonstrated up-
regulated expression levels in miR-21 in serum, plasma [81, 133] and hepatocytes 
[97] of CHC compared to healthy control. Again this inconsistency in the results 
might be attributed to variability in the prevalence of HCC and cirrhosis between the 
different populations. In addition to the presence of different genotypes that might 
show different expression in every mi-RNA.  
Regarding the diagnostic performance of miR-21 in HCC. Our results revealed 
that miR-21 was having a good diagnostic power to differentiate HCC patients from 
cirrhotic patients with (AUC=0.775), sensitivity=72.29% and specificity=50%. This 
comes in agreement with the results obtained from Yoshito Tomimaru et al. 
confirming that ROC curve results obtained from miR-21 expression could 
discriminated between HCC and those suffering from chronic hepatitis [98]. The 
former study has shown ROC analysis with (AUC= 0.773), sensitivity=61.61% and 
specificity=83.3%.   The previous data suggest that miR-21 can make a powerful 
marker investigating the prognosis from cirrhosis to HCC.  
Interestingly half of the total number of samples (n=78 out of n=156) gave 
undetectable cycle threshold Ct, even with multiple input of 2x dilution and 
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5microliter cDNA, with miR-155 after q RT-PCR operation regardless the category 
classification of the sample. Worth mentioning that several approaches were made to 
enhance the detection of this mi-RNA. First, higher concentration of extracted RNA 
had been used, instead of using 100ng of extracted RNA in poly-adenylation step, 
250ng, 300ng and 500ng of the undetectable samples were investigated with 
undetectable results in q RT-PCR as well. Additionally another trial was made 
elevating the concentration of utilized cDNA in the q RT-PCR step, rather than using 
2μl of 5x dilution of prepared cDNA, 5μl of 2x dilution of prepared cDNA was 
utilized with non-significant change in the primary results. Accordingly, these 
undetected samples were ignored and only samples that gave detectable values of Ct 
were utilized in calculations. 
Des-regulation of miR-155 had been investigated in different cancers.  These 
include breast, colon, lung [115] and large B-cell lymphoma (DLBCL) [129]. miR-
155 is proposed to play an important for host antiviral innate immune response [90, 
91]. Therefore, studying of the role of these microRNAs in HCV infection could help 
in understanding HCV molecular pathogenesis.  Our study revealed non-significant 
up regulation in miR-155 expression in HCC and healthy control compared to CHC 
and cirrhotic categories. Additionally, results illustrated non-significant down-
regulation in miR-155 expression in cirrhotic category compared to CHC, healthy 
control and HCC.   These results coincides with Nada El-Ekiaby et al study [95] on 
PBMC. Among the results of this Egyptian study that no significant difference was 
found regarding miR-155 expression levels in PBMCs of Egyptian patients genotype 
4 with chronic infection of HCV when being evaluated against healthy subjects. On 
the other hand, this was in contrary to another Egyptian study that was performed on 
serum samples of HCC and chronic hepatitis patients [78]. On one hand, a reason for 
this variation could be that the study conducted used serum rather than human plasma 
for their investigation. In addition, this might be due to the smaller no of samples 
employed for each category; utilizing around 20 samples for each category rather than 
employing around 40 samples. Finally, this study utilized RNU48 rather than 
synthetic miR-39 as reference for the samples. Moreover our results were opposite to 
others studies’ findings[134] performed on serum and monocytes samples using 18S 
as a normalizer and [135] performed on liver tissue that have reported significant up-
regulation in miR-155 expression in serum or plasma of CHC samples compared to 
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healthy control.  The study that had been performed on liver tissue utilized 30 HCC 
samples and 8 control, in addition to using U6 RNA as a normalizer. 
Logistic regression analysis revealed that combining miR-122, miR-21 and 
miR-155 might have a slight increase in the differentiation potential (AUC=0.723) 
between healthy control subjects and hepatocellular carcinoma patients. Additionally, 
combining miR-122 and miR-21 (AUC=0.809) might have a good increase in the 
differentiation potential between cirrhotic subjects and HCC patients. Finally, 
combing the three mi-RNAs (AUC=0.922) would have a promising diagnostic power 
to differentiate healthy control from cirrhotic patients. 
Our data demonstrated positive correlation between the three studied miRNAs 
in HCC patients only. Besides, our results have shown on one hand significant 
positive correlations between alfa feto protein levels and the expression levels of the 
three miRNAs. On the other hand, no correlations were found between the expressed 
miRNAs and AFP levels in cirrhosis category. This suggests concurrent expression of 
immune response related miRNAs in hepatocellular carcinoma subjects. Whether this 
concurrent expression of miR-122, miR-155 and miR-21 in HCC particular to HCV 
associated HCC remain unclear and needs more investigation. 
Finally, our study is limited by relatively moderate number of patients; 
however, it suggests that miR-122 can be utilized as a potential specific diagnostic 
biomarker for HCV associated HCC cases. Additionally, that miR-21 can investigate 
the prognosis from cirrhosis to HCC. Moreover, miR-155 would not be ideal as a 
prognostic marker in plasma of HCV related HCC patients of genotype-4. Additional 
studies are required to validate these data. 
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Chapter 6 CONCLUSIONS AND FUTURE PERSPECTIVES 
Current biomarkers for HCC diagnosis are lacking both sensitivity and 
specificity.  This necessitates the development of reliable biomarkers that are 
sensitive, specific and non-invasive for early diagnosis and rapid intervention of HCC 
to increase the survival rate of patients.  
In this study, we investigated mi-RNA expression profile from the plasma of 
Egyptian patients with chronic hepatitis C, cirrhosis and HCV associated HCC 
compared with healthy control. We aimed to assess the diagnostic potential of the 
selected miRNAs to differentiate between HCC and other HCV associated disorders. 
In addition to studying the expression pattern in the different studied stages.  
Using real time PCR, we compared the levels of circulating mir-122, miR-21 
and miR-155 in plasma from healthy control (n=40), cirrhosis (n=39) and HCC 
(n=40) to CHC (n=37). Synthetic miR-39 was spiked in the samples to be used as a 
normalizing control for the samples.  Plasma miR-122 was significantly up-regulated 
in HCC than in three other categories (P<0.001). The plasma level of miR-122 in 
HCC patients was significantly higher than healthy control and cirrhotic patients (P = 
0.002 and P<0.001, respectively). The plasma level of miR-21 was significantly up-
regulated in HCC compared to cirrhotic patients (P=0.03). This upregulation was 
found to be of marginal insignificance when compared to healthy control group. 
There had been no significant des-regulation in the expression levels of miR-155 
between the 4 categories. 
 ROC curves’ analysis revealed that miR-122 differentiated HCC patients 
from healthy control with a specificity and sensitivity 57.50% and 65.52%  
respectively (at a cutoff >1.86). To discriminate cirrhotic patients from HCC subjects, 
a specificity and sensitivity of 61.54% and 71.43% (at a cutoff> 0.43) were 
determined. Additionally, analyzing ROC curve indicated that miR-21 differentiated 
HCC patients from cirrhotic patients with best sensitivity and specificity 72.97% and 
50% (at a cutoff >-0.43).  
In conclusion, plasma miR-122, miR-21 may be used as sensitive and specific 
biomarkers for screening HCV associated HCC. Further studies are necessary to 
confirm the diagnostic value of the miR-122 and miR-21 as accurate plasma markers 
for HCC-associated HCV. 
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TABLES 
Table 1. Examples of direct and indirect biomarkers utilized to assess liver 
diseases’ severity 
Indirect biomarkers Direct biomarkers 
1. Aminotransferase (AST and 
ALT) 
1. ECM proteins (hyaluronic acid) 
2. Bilirubin 2. Matrix metalloproteases (MMPs) 
3. Gamma-glutamyl transpeptidase 
(GGT) 
3. MMP inhibitors [tissue inhibitors 
of matrix metalloproteases 
(TIMPs)] 
4. Prothrombin time 4. Fragments of procollagen III 
5. Albumin  
6. platelet (PLT) counts  
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Table 2. Demographic and clinical data of Healthy control, CHC, Cirrhosis and   
HCC 
Parameter Healthy 
control 
CHC Cirrhosis HCC P value 
Age (years) 46.82±1.68 45.43±1.54 57.46±0.91 47.10±1.68 <0.0001 
Range 
(years) 
 
21-65 25-64 43-76 21-65  
Sex     0.4622 
Male, n (%) 24 (60%) 25 (69.4%) 20 (51.3%) 24 (60%)  
Female, n (%) 16 (40%) 11(30.6%) 19 (48.7%) 16 (40%)  
ALT (IU/l) 9.86±1.17 48.65±8.67 46.61±6.8 74.48±12.07 <0.0001 
AST (IU/I) 13.60±2.08 40.74±6.42 64.31±8.2 118.56±19.41 <0.0001 
ALP (IU/I) 40.29±3.39 113.33±8.77 168.71±17.8 187.62±24.6 <0.0001 
Total 
bilirubin 
(mg/dl) 
 
0.73±0.09 1.00±0.19 4.07±0.98 3.44±0.85 0.004 
Albumin 
(g/dl) 
4.37±0.11 3.92±0.13 2.65±0.13 3.27±0.13 <0.0001 
Prothrombin 
time 
(sec) 
16.10±0.22 13.68±0.32 18.8±0.8 17.71±1.80 0.108 
Total 
Leukocyte 
count 
(x10³/mm³) 
4.92±0.22 4.82±0.45 7.15±0.65 7.35±0.42 0.014 
Platelet count 
(x10³/mm³) 
197.90±9.84 176.09±25.26 124.39±12.98 142.83±11.26 0.004 
 
Data are expressed by mean± standard error, or number (percentage) for gender. 
Statistical significance (P≤0.05).  
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Table 3. Clinical and virological data of CHC, Cirrhosis and HCC 
Parameter CHC Cirrhosis HCC P-Value 
Creatinine 
(mg/dl) 
0.79±0.05 1.18±0.1 1.13±0.10 0.105 
Urea 
(mg/dl) 
 
25±1.73 60.98±7.8 57.33±9.10 0.052 
INR 
 
1.13±0.05 1.61±0.08 1.55±0.14 0.104 
AFP 
(IU/ml) 
 
7.15±1.26 7.38±1.92 20.96±3.91 0.194 
Viral load 
log10 
(IU/ml) 
5.65±0.20 5.68±0.13 4.50±0.06 0.232 
Hemoglobin 
(mg/dl) 
14.66±0.77 10.65±0.39 11.61±0.31 <0.0001 
HbA1C 
(%) 
5.40±0.23 6.71±0.24 6.03±0.17 0.305 
RBC’s 
(106/mm³) 
4.75±0.24 3.64±0.11 4.14±0.12 0.001 
PCV 
(%) 
41.57±2.35 30.77±0.94 35.04±0.99 <0.0001 
MCV 
(µm³) 
84.74±3.19 85.36±1.64 81.77±2.14 0.465 
MCH 
(pg) 
27.39±1.43 27.71±0.65 27.52±0.55 0.969 
MCHC 
(g/dl) 
 
32.09±0.06 32.42±0.40 32.43±0.30 0.928 
RDW 
(%) 
19.85±3 17.85±0.55 17.54±0.69 0.729 
Data are expressed by mean± standard error. Statistical significance (P≤0.05). 
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Table 4. Water elution step trials’ for mi-RNA extraction optimization 
Trials on 10x dilution of synthetic miR-39 (100pg/ μl) Yield in % A260/A280 
1-a)Elution with 50 μl of dnase/rnase free water 16.1 2.147 
1-b)Elution with 50 μl of dnase/rnase free water on the 
same column 
5.56 1.706 
Total yield  21.66  
2-a) Elution with 2 times 25 μl of dnase/rnase free 
water 
14 1.969 
2-b) Elution with 1 time 25 μl of dnase/rnase free water 
on the same column 
27.5 1.493 
Total yield 41.5  
3-a) Elution with 3 times 16.5 μl of dnase/rnase free 
water 
132.68 1.642 
3-a) Elution with 1 time 16.5 μl of dnase/rnase free 
water on the same column 
3.5 1.655 
Total yield 136.18  
 
Table 5. Representative data of extracted RNA from different categories  
Sample 
no. 
Sample ID 260/280 Conc. (ng/μl) 
33 Control  1.381 13.04 
36 Control  1.149 27.2 
2 Control  0.994 39.96 
23 Control 0.939 19.32 
10 Fibrotic 0.728 24.44 
26 Fibrotic 0.73 47.84 
27 Fibrotic 0.703 28.12 
5 Fibrotic 0.842 49.28 
17 Cirrhotic  0.86 37.92 
23 Cirrhotic  0.867 16.08 
21 Cirrhotic  0.855 67.2 
10 Cirrhotic  0.862 13.28 
13 HCC  0.837 26.64 
10 HCC  1.001 44.28 
20   HCC   0.82 34.24 
21  HCC   0.839 47.6 
Mean± standard error of extracted RNA purity 260/280 is 0.9±0.01.  
Mean± standard error of extracted RNA concentration is 33.5±0.9. 
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Table 6. Poly-adenylation step optimization 
Concentration in ng Cycle threshold 
50 30.1 
100 27.67 
250 27.74 
500 27.92 
Different concentrations of total extracted RNA were investigated with corresponding 
cycle threshold. 
 
Table 7. q RT-PCR step optimization. 
Dilution Cycle threshold 
Stock 23.56 
2.5x 23.65 
5x 22.94 
10x 23.7 
Different concentrations of cDNA were investigated with corresponding cycle 
threshold. 
 
Table 8. mi-RNA annealing temperature optimization 
mi-RNA Ct at 50 ºC Ct at 55ºC Ct at 60 ºC Ct at 65 ºC Ct at 70 ºC 
miR-39 22.67 23.1 25.66 30.96 Undetected 
miR-122 33.1 32.31 34.26 38.98 Undetected 
miR-21 27.19 28.15 33.92 41.86 Un detected 
miR-155 38.93 42.17 Undetected Undetected Undetected 
Gradient temperatures were investigated for every mi-RNA to select the optimum 
annealing temperature. 
 
Table 9. Log2 fold change of plasma mi-RNA expression levels in healthy 
control, cirrhotic patients and HCC compared to CHC patients. 
mi-RNA Healthy 
control 
Cirrhosis HCC P value 
miR-122 0.88±0.65 0.00±0.57 5.45±1.31       <0.0001 
miR-155 4.12±1.13 -2.42±0.93 2.72±0.96 0.064 
miR-21 3.52±1.07 0.88±0.90 6±1.08 0.005 
Data are expressed by mean± standard error and were analyzed by one way anova.  
Statistical significance (P≤0.05). 
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Table 10. ROC curve analysis of plasma miR-122 as a diagnostic marker in 
patients with HCC  
miR-122 AUC P-Value 
Best cutoff 
value 
 (Log2 fold 
change) 
Sensitivity 
% 
Specificity 
% 
PPV 
% 
NPV 
% 
Control 0.705 0.002 >1.86 65.52 57.50 52.75 69.72 
Cirrhotic 0.767 <0.0001 >0.43 71.43 61.54 57.15 75 
PPV; positive predictive value. NPV; negative predictive value. 
 
Table 11. ROC curve analysis of plasma miR-21 as a diagnostic marker in 
patients with HCC  
miR-21 AUC P-Value 
Best cutoff 
value 
 (Log2 fold 
change) 
Sensitivity 
% 
Specificity 
% 
PPV 
% 
NPV 
% 
Cirrhotic 0.775 <0.0001 >-0.46 72.97 50 65.9 58.3 
PPV; positive predictive value. NPV; negative predictive value. 
 
Table 12. Significant correlation between studied plasma mi-RNA in healthy 
control 
mi-RNA miR-122 miR-155 miR-21 
miR-122 - r=0.472 
P=0.020 
NS 
miR-155 r=0.472 
P=0.20 
- NS 
miR-21 NS NS - 
Association between mi-RNA levels were determined in healthy control (n=40) using 
Pearson correlation. r: Pearson rho coefficient, NS: non-significant (P>0.05). 
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Table 13. Significant correlation between studied plasma mi-RNA in Cirrhotic 
patients 
mi-RNA miR-122 miR-155 miR-21 
miR-122 - NS NS 
miR-155 NS - NS 
miR-21 NS NS - 
Association between mi-RNA levels were determined in Cirrhotic patients (n=39) 
using Pearson correlation. r: Pearson rho coefficient, NS: non-significant (P>0.05). 
 
Table 14. Significant correlation between studied plasma mi-RNA in HCC 
patients 
mi-RNA miR-122 miR-155 miR-21 
miR-122 - r=0.681 
P=0.004 
r=0.789 
p<0.001 
miR-155 r=0.681 
P=0.004 
- r=0.684 
p=0.005 
miR-21 r=0.789 
p<0.001 
r=0.684 
P=0.005 
- 
Association between mi-RNA levels were determined in HCC patients (n=40) using 
Pearson correlation. r: Pearson rho coefficient, NS: non-significant (P>0.05). 
 
Table 15. Logistic regression analysis to differentiate healthy control subjects 
from HCC patients utilizing mi-RNAs combinations 
Selected miRNA Area under the curve P-Value 
miR-122 0.705 0.002 
miR-21 0.567 0.0064 
miR-122 and miR-21 0.703 0.0002 
miR-122 and miR-155 0.688 0.0261 
miR-21 and miR-155 0.575 0.8632 
miR-122, miR-21 and miR-155 0.723 0.049 
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Table 16. Logistic regression analysis to differentiate cirrhotic subjects from 
HCC patients utilizing mi-RNAs combinations 
Selected miRNA Area under the curve P-Value 
miR-122 0.767 <0.0001 
miR-21 0.775 <0.0001 
miR-122 and miR-21 0.809 <0.0001 
miR-122 and miR-155 0.760 0.0428 
miR-21 and miR-155 0.792 0.0272 
miR-122, miR-21 and miR-155 0.839 0.0575 
 
Table 17. Logistic regression analysis to differentiate healthy control subjects 
from cirrhotic patients utilizing mi-RNAs combinations 
Selected miRNA Area under the curve P-Value 
miR-122 0.599 0.3077 
miR-122 and miR-21 0.745 0.0147 
miR-122 and miR-155 0.765 0.0474 
miR-122, miR-21 and miR-155 0.922 0.0007 
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Table 18. Collection of studies performed on miR-122 
No of 
patients 
Type 
of 
sample 
Category Genotype
/Region 
Assay-
used 
Results Reference 
190 Serum HCC, 
chronic 
hepatitis 
B 
China Quantitative 
real time pcr 
miR-122 was 
upregulated in 
HCC compared 
to healthy 
control. miR-
122 was 
upregulated in 
CHC compared 
to HCC. 
101 
384 Serum CHC, 
cirrhosis 
and 
HCC 
Egypt* Quantitative 
real time pcr 
miR-122 was 
significantly 
upregulated in 
HCC compared 
to healthy 
control and 
cirrhotic 
patients. 
115 
- Cell line 
and 
liver 
tissue 
HCC Germany Quantitative 
real time pcr 
miR-122 was 
up regulated in 
HCC samples 
compared to 
healthy control 
116 
75 serum CHC, 
cirrhosis 
and 
HCC 
Egypt* Quantitative 
real time pcr 
miR-122 was 
significantly 
upregulated in 
the three 
diseased groups 
compared to 
healthy control 
124 
- Liver 
tissue 
CHC USA Quantitative 
real time pcr 
miR-122 was 
downregulated 
in CHC. 
125 
- Liver 
tissue 
CHC USA Microarray miR-122 was 
down regulated 
in HCC. 
126 
249 Serum Cirrhosi
s and 
HCC 
 Quantitative 
real time pcr 
miR-122 levels 
didn’t differ 
significantly 
between 
cirrhosis and 
HCC 
127 
54 
116 Plasma CHC, 
Cirrhosi
s and 
HCC 
Egypt* Quantitative 
real time pcr 
miR-122 was 
significantly up 
regulated in 
HCC cases 
compared to 
healthy control 
and cirrhotic. 
There had been 
non-significant 
up regulation in 
cirrhotic group 
compared to 
healthy control. 
Our study 
*Studies that were performed in Egypt. Our study was listed at last in the table.  
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FIGURES 
 
 
Figure 1. Annual deaths from viral hepatitis, tuberculosis, HIV and Malaria. The 
incidence of viral hepatitis deaths is increasing over time. Retrieved from [8]. 
 
 
 
 
Figure 2. An illustration of the viraemic HCV prevalence and the concluded total 
HCV cases for each country. Retrieved from [9]. 
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Figure 3. Global prevalence of HCV infection by WHO. The Eastern 
Mediterranean region has the highest prevalence of HCV. Retrieved from [8]. 
 
 
 
 
Figure 4. HCV particle structure. HCV particle is made up of an envelope with 
glycoproteins, a nucleocapsid and the viral genome. Retrieved from [136]. 
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Figure 5. HCV Virology. (a) Structure of the HCV genome and (b) summary of 
HCV polyprotein processing. Retrieved from [17]. 
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Figure 6. Hepatitis C virus life cycle.  Retrieved from [9] 
 
 
 
 
Figure 7. HCV genotypes global prevalence.  Retrieved from [26] 
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Figure 8. HCV and immune response. Adaptive immune response, CD8+ cells have 
antiviral activity through either cytolysis or non-cytolysis activity. Retrieved from 
[32]. 
 
 
 
 
Figure 9. HCV ability to evade host immune response. Retrieved from [137]. 
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Figure 10. HCV prognosis to HCC. Pathogenesis of HCC derived HCV involves 
multiple steps and different associated biological drivers. Retrieved from [40] 
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Figure 11. Different available DAA. Retrieved from [53] 
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Figure 12. mi-RNA biogenesis. Retrieved from [57] 
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Figure 13. Modes of mi-RNA packaging after their biogenesis. There are three   
packs of extracellular mi-RNAs, either packed in apoptotic bodies, shedding 
vesicles or exosomes. Retrieved from [73] 
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Figure 14. Demographic data of healthy controls (n=40), CHC (n=37), Cirrhosis 
(n=39) and HCC (n=40). A) Age (mean ± standard error) and B) Gender (% 
within the group). 
 
 
 
4
7
.1
0
4
5
.4
3
5
7
.4
6
6
0
.4
1
H E A L T H Y  C O N T R O L C H C C I R R H O T I C H C C
A
G
E 
(Y
EA
R
S)
A
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Healthy control CHC Cirrhotic HCC
G
en
d
er
 (
%
 w
it
h
in
 t
h
e 
gr
o
u
p
)
B
Male Female
P<0.0001 
P=0.4622 
65 
  
 
 
 
Figure 15. Serum activities of liver enzymes (ALT, AST and ALP) in healthy controls 
(n=40), CHC (n=37), Cirrhosis (n=39) and HCC (n=40). Data are expressed by means 
± standard error. 
 
 
 
 
 
 
 
Figure 16. Serum Albumin levels in healthy controls (n=40), CHC (n=37), 
Cirrhosis (n=39) and HCC (n=40). Data are expressed by means ± standard 
error. 
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Figure 17. Serum total bilirubin levels in healthy controls (n=40), CHC (n=37), 
Cirrhosis (n=39) and HCC (n=40). Data are expressed by means ± standard 
error.    
 
 
 
 
 
 
Figure 18. Prothrombin time in healthy controls (n=40), CHC (n=37), Cirrhosis 
(n=39) and HCC (n=40). Data are expressed by means ± standard error. 
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Figure 19. Hematological data in healthy controls (n=40), CHC (n=37), Cirrhosis 
(n=39) and HCC (n=40). Data are expressed by means ± standard error. 
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Figure 20. Alfa feto protein levels in CHC (n=37), Cirrhosis (n=39) and HCC 
(n=40). Data are expressed by means ± standard error. 
 
 
 
 
 
Figure 21. Log10 viral load levels in CHC (n=37), Cirrhosis (n=39) and HCC 
(n=40). Data are expressed by means ± standard error. 
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Figure 22. Serum creatinine and urea levels CHC (n=37), Cirrhosis (n=39) and 
HCC (n=40). Data are expressed by means ± standard error.  
 
 
 
 
 
Figure 23. Packed cell volume and red blood cell distribution width distribution 
in CHC (n=37), Cirrhosis (n=39) and HCC (n=40). Data are expressed by means 
± standard error. 
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Figure 24. Mean corpuscular volume in CHC (n=37), Cirrhosis (n=39) and HCC 
(n=40). Data are expressed by means ± standard error. 
 
 
 
 
Figure 25. Mean corpuscular hemoglobin in CHC (n=37), Cirrhosis (n=39) and 
HCC (n=40). Data are expressed by means ± standard error. 
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Figure 26. Mean corpuscular hemoglobin concentration in CHC (n=37), Cirrhosis 
(n=39) and HCC (n=40). Data are expressed by means ± standard error. 
 
 
 
 
Figure 27. RBC’s count and hemoglobin level in CHC (n=37), Cirrhosis (n=39) 
and HCC (n=40). Data are expressed by means ± standard error. 
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Figure 28. Hemoglobin level in CHC (n=37), Cirrhosis (n=39) and HCC (n=40). 
Data are expressed by means ± standard error. 
 
 
 
 
 
 
 
Figure 29. Assessment of extrinsic coagulation pathway using international 
normalized ratio in CHC (n=37), Cirrhosis (n=39) and HCC (n=40). Data are 
expressed by means ± standard error.  
 
0.00
2.00
4.00
6.00
8.00
10.00
12.00
14.00
16.00
18.00
CHC Cirrhosis HCC
H
e
m
o
gl
ib
in
 le
ve
l (
g/
d
l)
0.00
0.20
0.40
0.60
0.80
1.00
1.20
1.40
1.60
1.80
CHC Cirrhosis HCC
IN
R
P<0.0001 
P=0.104 
73 
 
Figure 30. Poly adenylation step optimization. Serial concentrations of total 
extracted RNA had been tried (50ng, 250ng, 100ng and 500ng). 
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Figure 31. q RT-PCR step optimization. (A) Amplification plot of different 
cDNA dilutions (stock, 2.5x, 5x and 10x). (B) The melt curve of these dilutions. 
The melt curve is showing single peaks for all dilutions. 
B 
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Figure 32. miR-39 annealing temperature optimization.  (A) Amplification plot 
of miR-39 at different annealing temperatures. (B) The melt curve of these 
temperatures. The melt curve is showing single peaks for all temperatures except 
for temp 70 ºC that have shown undetectable Ct. 
. 
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Figure 33. miR-122 annealing temperature optimization.  (A) Amplification plot 
of miR-122 at different annealing temperatures. (B) The melt curve of these 
temperatures. The melt curve is showing single peaks for all temperatures except 
for temp 70 ºC that have shown undetectable Ct. 
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Figure 34. miR-21 annealing temperature optimization.  (A) Amplification plot 
of miR-21 at different annealing temperatures.  (B) The melt curve of these 
temperatures. The melt curve is showing single peaks for all temperatures except 
for temp 70 ºC that have shown undetectable Ct. 
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Figure 35. miR-155 annealing temperature optimization. (A) Amplification plot 
of miR-155 at different annealing temperatures. (B) The melt curve of these 
temperatures. The melt curve is showing single peaks for all temperatures except 
for temp 60 ºC., 65 ºC and 70 ºC that have shown undetectable Ct. 
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Figure 36. Differential expression of plasma mi-RNAs in healthy control subjects 
(n=40) compared to CHC (n=37). Data are presented as mean± standard error.  
 
 
 
 
Figure 37. Differential expression of plasma mi-RNAs in Cirrhotic subjects (n=39) 
compared to CHC (n=37). Data are presented as mean± standard error. 
 
 
 
 
 
Figure 38. Differential expression of plasma mi-RNAs in HCC subjects (n=40) 
compared to CHC (n=37). Data are presented as mean± standard error. 
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Figure 39. Plasma miR-122 as diagnostic marker of HCC. ROC curve analysis of 
plasma mi-122 expression as diagnostic biomarker to differentiate HCC patients 
(n=40) from healthy control (n=40).  
 
 
Figure 40. Plasma miR-122 as diagnostic marker of HCC. ROC curve analysis of 
plasma mi-122 expression as diagnostic biomarker to differentiate HCC patients 
(n=40) from cirrhotic patients (n=39).  
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Figure 41. Plasma miR-21 as diagnostic marker for cirrhosis. ROC curve analysis 
of plasma mi-21 expression as diagnostic biomarker to differentiate cirrhotic 
patients (n=39) from HCC patients (n=40).  
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Figure 42. Correlation between plasma miRNA levels and AFP in HCC patients. 
Association were determined using Pearson correlation, r: Pearson rho 
coefficient. 
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